{"id": "0147472a-6ae3-4fa5-8440-acc92b082f30", "page": 1, "type": "table", "data": [["", "Morbidity and Mortality Weekly Report"], ["Recommendations and Reports / Vol. 71 / No. 1", "August 26, 2022"], ["Prevention and Control of Seasonal Influenza with", ""], ["Vaccines: Recommendations of the Advisory", ""], ["Committee on Immunization Practices \u2014", ""], ["United States, 2022\u201323 Influenza Season", ""], ["", "U.S. Department of Health and Human Services"], ["", "Centers for Disease Control and Prevention"]]}
{"id": "f5868f00-91dc-493c-ab6f-8563543e86af", "page": 2, "type": "table", "data": [["", "Recommendations and Reports"], ["CONTENTS", "CDC Adoption of ACIP Recommendations for MMWR"], ["", "Recommendations and Reports, MMWR Policy Notes, and"], ["Introduction ............................................................................................................2", "Immunization Schedules (Child/Adolescent, Adult)"], ["Methods ....................................................................................................................2", "Recommendations  for  routine  use  of  vaccines  in  children,"], ["", "adolescents,  and  adults  are  developed  by  the  Advisory"], ["Primary Changes and Updates .........................................................................6", ""], ["", "Committee  on  Immunization  Practices  (ACIP).  ACIP  is"], ["Recommendations for the Use of Influenza Vaccines, 2022\u201323 ...........7", ""], ["", "chartered as a Federal Advisory Committee to provide expert"], ["Influenza Vaccine Composition and Available Vaccines ...................... 17", "external  advice  and  guidance  to  the  Director  of  CDC  on"], ["", "use of vaccines and related agents for the control of vaccine"], ["Storage and Handling of Influenza Vaccines ............................................ 20", ""], ["", "preventable diseases in the civilian population of the United"], ["Additional Sources of Information Regarding Influenza and", ""], ["", "States. Recommendations for routine use of vaccines in children"], ["Influenza Vaccines ........................................................................................... 21", "and adolescents are harmonized to the greatest extent possible"], ["", "with  recommendations  made  by  the  American  Academy  of"], ["References ............................................................................................................. 22", ""], ["", "Pediatrics (AAP), the American Academy of Family Physicians"], ["", "(AAFP),  and  the  American  College  of  Obstetricians  and"], ["", "Gynecologists (ACOG). Recommendations for routine use of"], ["", "vaccinations in adults are harmonized with recommendations"], ["", "of  AAFP,  ACOG,  and  the  American  College  of  Physicians"], ["", "(ACP).  ACIP  recommendations  approved  by  the  CDC"], ["", "Director become agency guidelines on the date published in the"], ["", "Morbidity and Mortality Weekly Report (MMWR). Additional"], ["", "information is available at https://www.cdc.gov/vaccines/acip."]]}
{"id": "01395966-800a-4b87-a4c2-bd216654450b", "page": 2, "type": "table", "data": [["", "Jennifer Layden, MD, PhD, Deputy Director, Office of Science", ""], ["", "Leslie Dauphin, PhD, Director, Center for Surveillance, Epidemiology, and Laboratory Services", ""], ["", "MMWR Editorial and Production Staff (Serials)", ""], ["Charlotte K. Kent, PhD, MPH, Editor in Chief", "Martha F. Boyd, Lead Visual Information Specialist", ""], ["", "", "Ian Branam, MA,"], ["Brian A. King, PhD, MPH, Executive Editor", "Alexander J. Gottardy, Maureen A. Leahy,", ""], ["", "", "Acting Lead Health Communication Specialist"], ["Christine G. Casey, MD, Editor", "Julia C. Martinroe, Stephen R. Spriggs,Tong Yang,", "Shelton Bartley, MPH, Symone Hairston, MPH"], ["Mary Dott, MD, MPH, Online Editor", "Visual Information Specialists", "Leslie Hamlin, Lowery Johnson,"], ["Terisa F. Rutledge, Managing Editor", "Quang M. Doan, MBA, Phyllis H. King,", "Health Communication Specialists"], ["David C. Johnson, Lead Technical Writer-Editor", "Terraye M. Starr, Moua Yang,", "Will Yang, MA,"], ["Marella Meadows, Project Editor", "Information Technology Specialists", "Visual Information Specialist"], ["", "MMWR Editorial Board", ""], ["", "Timothy F. Jones, MD, Chairman", ""], ["Matthew L. Boulton, MD, MPH", "David W. Fleming, MD", "Patricia Quinlisk, MD, MPH"], ["Carolyn Brooks, ScD, MA", "William E. Halperin, MD, DrPH, MPH", "Patrick L. Remington, MD, MPH"], ["Jay C. Butler, MD", "Jewel Mullen, MD, MPH, MPA", "Carlos Roig, MS, MA"], ["Virginia A. Caine, MD", "Jeff Niederdeppe, PhD", "William Schaffner, MD"], ["Jonathan E. Fielding, MD, MPH, MBA", "Celeste Philip, MD, MPH", "Morgan Bobb Swanson, BS"]]}
{"id": "f7b67e2d-fa92-424c-9195-45970d30b937", "page": 3, "type": "table", "data": [["Zoonotic Infectious Diseases, CDC; 3Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee; 4Department of Health Research", ""], ["", "Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"], ["", "Summary"], ["", "This report updates the 2021\u201322 recommendations of the Advisory Committee on Immunization Practices (ACIP) concerning"], ["", "the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2021;70[No. RR-5]:1\u201324). Routine annual"], ["", "influenza vaccination is recommended for all persons aged \u22656 months who do not have contraindications. For each recipient,"], ["", "a  licensed  and  age-appropriate  vaccine  should  be  used.  With  the  exception  of  vaccination  for  adults  aged  \u226565  years,  ACIP"], ["", "makes no preferential recommendation for a specific vaccine when more than one licensed, recommended, and age-appropriate"], ["", "vaccine is available. All seasonal influenza vaccines expected to be available in the United States for the 2022\u201323 season are"], ["", "quadrivalent, containing hemagglutinin (HA) derived from one influenza A(H1N1)pdm09 virus, one influenza A(H3N2) virus,"], ["", "one influenza B/Victoria lineage virus, and one influenza B/Yamagata lineage virus. Inactivated influenza vaccines (IIV4s),"], ["", "recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Trivalent"], ["influenza vaccines are no longer available, but data that involve these vaccines are included for reference.", ""], ["", "Influenza vaccines might be available as early as July or August, but for most persons who need only 1 dose of influenza vaccine"], ["", "for the season, vaccination should ideally be offered during September or October. However, vaccination should continue after"], ["", "October and throughout the season as long as influenza viruses are circulating and unexpired vaccine is available. For most adults"], ["", "(particularly adults aged \u226565 years) and for pregnant persons in the first or second trimester, vaccination during July and August"], ["", "should be avoided unless there is concern that vaccination later in the season might not be possible. Certain children aged 6 months"], ["", "through 8 years need 2 doses; these children should receive the first dose as soon as possible after vaccine is available, including"], ["", "during July and August. Vaccination during July and August can be considered for children of any age who need only 1 dose for"], ["the season and for pregnant persons who are in the third trimester if vaccine is available during those months.", ""], ["", "Updates  described  in  this  report  reflect  discussions  during  public  meetings  of  ACIP  that  were  held  on  October  20,  2021;"], ["", "January 12, 2022; February 23, 2022; and June 22, 2022. Primary updates to this report include the following three topics:"], ["", "1) the composition of 2022\u201323 U.S. seasonal influenza vaccines; 2) updates to the description of influenza vaccines expected"], ["", "to be available for the 2022\u201323 season, including one influenza vaccine labeling change that occurred after the publication of"], ["", "the 2021\u201322 ACIP influenza recommendations; and 3) updates to the recommendations concerning vaccination of adults aged"], ["", "\u226565 years. First, the composition of 2022\u201323 U.S. influenza vaccines includes updates to the influenza A(H3N2) and influenza"], ["", "B/Victoria lineage components. U.S.-licensed influenza vaccines will contain HA derived from an influenza A/Victoria/2570/2019"], ["", "(H1N1)pdm09-like virus (for egg-based vaccines) or an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like virus (for cell"], ["", "culture\u2013based or recombinant vaccines); an influenza A/Darwin/9/2021 (H3N2)-like virus (for egg-based vaccines) or an influenza"], ["", "A/Darwin/6/2021 (H3N2)-like virus (for cell culture\u2013based or recombinant vaccines); an influenza B/Austria/1359417/2021"], ["", "(Victoria lineage)-like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus. Second, the approved age"], ["", "indication for the cell culture\u2013based inactivated influenza vaccine, Flucelvax Quadrivalent (ccIIV4), was changed in October"], ["", "2021 from \u22652 years to \u22656 months. Third, recommendations for vaccination of adults aged \u226565 years have been modified. ACIP"], ["", "recommends that adults aged \u226565 years preferentially receive any one of the following higher dose or adjuvanted influenza vaccines:"], ["", "quadrivalent  high-dose  inactivated  influenza  vaccine  (HD-IIV4),  quadrivalent  recombinant  influenza  vaccine  (RIV4),  or"], ["", "quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity for"], ["", "vaccine administration, then any other age-appropriate influenza"], ["Corresponding  author:  Lisa  A.  Grohskopf,  Influenza  Division,", "vaccine should be used."], ["National Center for Immunization and Respiratory Diseases, CDC.", ""], ["", "This report focuses on recommendations for the use of vaccines"], ["Telephone: 404-639-2552; Email: lgrohskopf@cdc.gov.", ""], ["", "for the prevention and control of seasonal influenza during the"]]}
{"id": "18a4c3dc-3663-486e-a637-4138cc1b90f3", "page": 4, "type": "table", "data": [["These recommendations apply to U.S.-licensed influenza vaccines used according to Food and Drug Administration\u2013licensed"], ["indications. Updates and other information are available from CDC\u2019s influenza website (https://www.cdc.gov/flu). Vaccination"], ["and health care providers should check this site periodically for additional information."], ["2021\u201322 season, although severity indicators (e.g., influenza-"], ["Introduction"], ["associated hospitalizations and deaths) were overall lower than"], ["Influenza viruses typically circulate annually in the United"], ["in recent previous seasons (16). Timing, intensity, and severity"], ["States, most commonly from the late fall through the early"], ["of the 2022\u201323 influenza season cannot be predicted. Influenza"], ["spring.  Most  persons  who  become  ill  after  influenza  virus"], ["vaccination remains an important tool for the prevention of"], ["infection recover without serious complications or sequelae."], ["potentially  severe  respiratory  illness,  which  might  decrease"], ["However,  influenza  can  be  associated  with  serious  illnesses,"], ["stress on the U.S. health care system during ongoing circulation"], ["hospitalizations, and deaths, particularly among older adults,"], ["of SARS-CoV-2. Guidance for vaccine planning during the"], ["very young children, pregnant persons, and persons of all ages"], ["COVID-19  pandemic  is  available  at  https://www.cdc.gov/"], ["with certain chronic medical conditions (1\u20137). Influenza also is"], ["vaccines/pandemic-guidance/index.html."], ["an important cause of missed work and school (8\u201310). Routine"], ["This report updates the 2021\u201322 ACIP recommendations"], ["annual influenza vaccination for all persons aged \u22656 months"], ["regarding  the  use  of  seasonal  influenza  vaccines  (17)  and"], ["who do not have contraindications has been recommended by"], ["provides  recommendations  and  guidance  for  vaccination"], ["CDC and the Advisory Committee on Immunization Practices"], ["providers  regarding  the  use  of  influenza  vaccines  in  the"], ["(ACIP) since 2010 (11)."], ["United States for the 2022\u201323 season. Various formulations"], ["Vaccination provides important protection from influenza"], ["of influenza vaccines are available (Table 1). Contraindications"], ["illness  and  its  potential  complications. The  effectiveness  of"], ["and  precautions  for  the  use  of  influenza  vaccines  are"], ["influenza  vaccination  varies  depending  on  several  factors,"], ["summarized (Tables 2 and 3). Abbreviations are used in this"], ["such as the age and health of the recipient; the type of vaccine"], ["report to denote the various types of vaccines (Box)."], ["administered; the types, subtypes (for influenza A), and lineages"], ["This  report  focuses  on  recommendations  and  guidance"], ["(for influenza B) of circulating influenza viruses; and the degree"], ["for the use of seasonal influenza vaccines for the prevention"], ["of similarity between circulating viruses and those included in"], ["and control of influenza during the 2022\u201323 season in the"], ["the vaccine (12). During each of the six influenza seasons from"], ["United States. A summary of these recommendations and a"], ["2010\u201311 through 2015\u201316, influenza vaccination prevented"], ["Background Document containing additional information on"], ["an estimated 1.6\u20136.7 million illnesses, 790,000\u20133.1 million"], ["influenza, influenza-associated illness, and influenza vaccines"], ["outpatient medical visits, 39,000\u201387,000 hospitalizations, and"], ["are  available  at  https://www.cdc.gov/vaccines/hcp/acip-recs/"], ["3,000\u201310,000 respiratory and circulatory deaths each season"], ["vacc-specific/flu.html."], ["in the United States (13). During the severe 2017\u201318 season,"], ["notable  for  an  unusually  long  duration  of  widespread  high"], ["influenza  activity  throughout  the  United  States  and  higher"], ["Methods"], ["rates of outpatient visits and hospitalizations compared with"], ["ACIP  provides  annual  recommendations  for  the  use  of"], ["recent seasons, vaccination prevented an estimated 7.1 million"], ["influenza vaccines for the prevention and control of seasonal"], ["illnesses, 3.7 million medical visits, 109,000 hospitalizations,"], ["influenza  in  the  United  States. The  ACIP  Influenza  Work"], ["and 8,000 deaths (14), despite an overall estimated vaccine"], ["Group  meets  by  teleconference  once  to  twice  per  month"], ["effectiveness of 38% (62% against influenza A[H1N1]pdm09"], ["throughout the year. Work group membership includes several"], ["viruses,  22%  against  influenza  A[H3N2]  viruses,  and  50%"], ["voting  members  of  ACIP,  representatives  of  ACIP  liaison"], ["against influenza B viruses) (14)."], ["organizations,  and  consultants.  Discussions  include  topics"], ["Influenza circulated at historically low levels in the United"], ["such as influenza surveillance, vaccine effectiveness and safety,"], ["States  and  globally  during  the  2020\u201321  influenza  season"], ["vaccination  coverage,  program  feasibility,  cost  effectiveness,"], ["(15). This  was  coincident  with  widespread  implementation"], ["and vaccine supply. Presentations are requested from invited"], ["of  nonpharmaceutical  interventions  (e.g.,  masking,  social"], ["experts, and published and unpublished data are discussed."], ["distancing,  and  suspension  of  in-person  work  and  school)"], ["The Background Document that supplements this report is"], ["intended to prevent transmission of SARS-CoV-2 (the virus"], ["updated periodically to reflect recent additions to the literature"], ["that causes COVID-19). Influenza activity increased during the"]]}
{"id": "e62c1372-b004-4616-b382-ef0b61611f8e", "page": 5, "type": "table", "data": [["", "", "Recommendations and Reports", "", "", ""], ["", "TABLE 1. Influenza vaccines \u2014 United States, 2022\u201323 influenza season*", "", "", "", ""], ["", "", "", "\u00b5g HA (IIV4s and RIV4)", "", "Mercury"], ["", "", "", "or virus count (LAIV4)", "", "(from thimerosal, if present),"], ["Trade name (manufacturer)", "Presentations", "Age indication", "for each vaccine virus (per dose)", "Route", "\u00b5g/0.5 mL"], ["IIV4 (standard-dose, egg-based vaccines\u2020)", "", "", "", "", ""], ["Afluria Quadrivalent", "0.5-mL PFS\u00a7", "\u22653 yrs\u00a7", "15 \u00b5g/0.5 mL", "IM\u00b6", "\u2014**"], ["(Seqirus)", "5.0-mL MDV\u00a7", "\u22656 mos\u00a7", "7.5 \u00b5g/0.25 mL", "IM\u00b6", "24.5"], ["", "", "(needle and syringe)", "15 \u00b5g/0.5 mL", "", ""], ["", "", "18 through 64 yrs", "", "", ""], ["", "", "(jet injector)", "", "", ""], ["Fluarix Quadrivalent", "0.5-mL PFS", "\u22656 mos", "15 \u00b5g/0.5 mL", "IM\u00b6", "\u2014"], ["(GlaxoSmithKline)", "", "", "", "", ""], ["FluLaval Quadrivalent", "0.5-mL PFS", "\u22656 mos", "15 \u00b5g/0.5 mL", "IM\u00b6", "\u2014"], ["(GlaxoSmithKline)", "", "", "", "", ""], ["Fluzone Quadrivalent", "0.5-mL PFS\u2020\u2020", "\u22656 mos\u2020\u2020", "15 \u00b5g/0.5 mL", "IM\u00b6", "\u2014"], ["(Sanofi Pasteur)", "0.5-mL SDV\u2020\u2020", "\u22656 mos\u2020\u2020", "15 \u00b5g/0.5 mL", "IM\u00b6", "\u2014"], ["", "5.0-mL MDV\u2020\u2020", "\u22656 mos\u2020\u2020", "7.5 \u00b5g/0.25 mL", "IM\u00b6", "25"], ["", "", "", "15 \u00b5g/0.5 mL", "", ""], ["ccIIV4 (standard-dose, cell culture\u2013based vaccine)", "", "", "", "", ""], ["Flucelvax Quadrivalent", "0.5-mL PFS", "\u22656 mos", "15 \u00b5g/0.5 mL", "IM\u00b6", "\u2014"], ["(Seqirus)", "5.0-mL MDV", "\u22656 mos", "15 \u00b5g/0.5 mL", "IM\u00b6", "25"], ["HD-IIV4 (high-dose, egg-based vaccine\u2020)", "", "", "", "", ""], ["Fluzone High-Dose Quadrivalent", "0.7-mL PFS", "\u226565 yrs", "60 \u00b5g/0.7 mL", "IM\u00b6", "\u2014"], ["(Sanofi Pasteur)", "", "", "", "", ""], ["", "aIIV4 (standard-dose, egg-based vaccine\u2020 with MF59 adjuvant)", "", "", "", ""], ["Fluad Quadrivalent", "0.5-mL PFS", "\u226565 yrs", "15 \u00b5g/0.5 mL", "IM\u00b6", "\u2014"], ["(Seqirus)", "", "", "", "", ""], ["RIV4 (recombinant HA vaccine)", "", "", "", "", ""], ["Flublok Quadrivalent", "0.5-mL PFS", "\u226518 yrs", "45 \u00b5g/0.5 mL", "IM\u00b6", "\u2014"], ["(Sanofi Pasteur)", "", "", "", "", ""], ["LAIV4 (egg-based vaccine\u2020)", "", "", "", "", ""], ["FluMist Quadrivalent", "0.2-mL prefilled single-", "2 through 49 yrs", "106.5\u20137.5 fluorescent", "NAS", "\u2014"], ["(AstraZeneca)", "use intranasal sprayer", "", "focus units/0.2 mL", "", ""], ["Abbreviations: ACIP = Advisory Committee on Immunization Practices; FDA = Food and Drug Administration; HA = hemagglutinin; IIV4 = inactivated influenza", "", "", "", "", ""], ["vaccine, quadrivalent; IM = intramuscular; LAIV4 = live attenuated influenza vaccine, quadrivalent; MDV = multidose vial; NAS = intranasal; PFS = prefilled syringe;", "", "", "", "", ""], ["RIV4 = recombinant influenza vaccine, quadrivalent; SDV = single-dose vial.", "", "", "", "", ""], ["", "* Vaccination providers should consult FDA-approved prescribing information for 2022\u201323 influenza vaccines for the most complete and updated information,", "", "", "", ""], ["", "including but not limited to indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at https://www.fda.", "", "", "", ""], ["", "gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states. Availability and characteristics of specific products and presentations might change", "", "", "", ""], ["", "or differ from what is described in this table and in the text of this report.", "", "", "", ""], ["", "\u2020 Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV4s and LAIV4, ACIP recommends", "", "", "", ""], ["", "that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status.", "", "", "", ""], ["", "Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema or swelling, respiratory distress, lightheadedness, or", "", "", "", ""], ["", "recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated in an inpatient or outpatient medical setting", "", "", "", ""], ["", "(including but not necessarily limited to hospitals, clinics, health departments, and physician offices) supervised by a health care provider who is able to recognize", "", "", "", ""], ["", "and manage severe allergic reactions, if a vaccine other than ccIIV4 or RIV4 is used.", "", "", "", ""], ["", "\u00a7 The approved dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for persons aged \u22653 years. However, 0.25-mL", "", "", "", ""], ["", "prefilled syringes are not expected to be available for the 2022\u201323 season. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a", "", "", "", ""], ["multidose vial.", "", "", "", "", ""], ["", "\u00b6 IM-administered influenza vaccines should be given by needle and syringe only, with the exception of the MDV presentation of Afluria Quadrivalent, which may", "", "", "", ""], ["", "alternatively be given by the PharmaJet Stratis jet injector for persons aged 18 through 64 years only. For adults and older children, the recommended site for", "", "", "", ""], ["", "intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Additional", "", "", "", ""], ["", "specific guidance regarding site selection and needle length for intramuscular administration is available in the ACIP General Best Practice Guidelines for Immunization,", "", "", "", ""], ["", "available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.", "", "", "", ""], ["** Not applicable.", "", "", "", "", ""], ["", "\u2020\u2020 Fluzone Quadrivalent is currently approved for ages 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL prefilled syringes are not expected", "", "", "", ""], ["", "to be available for the 2022\u201323 influenza season. If a prefilled syringe of Fluzone Quadrivalent is used for a child in this age group, the dose volume will be 0.5 mL", "", "", "", ""], ["per dose.", "", "", "", "", ""]]}
{"id": "a6f3becc-826f-4eeb-96a7-f9893a0a4737", "page": 5, "type": "table", "data": [["\u2020\u2020 Fluzone Quadrivalent is currently approved for ages 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL prefilled syringes are not expected", ""], ["", "to be available for the 2022\u201323 influenza season. If a prefilled syringe of Fluzone Quadrivalent is used for a child in this age group, the dose volume will be 0.5 mL"], ["per dose.", ""], ["related  to  recommendations  made  in  previous  seasons  and", "reflect use that is consistent with indications and prescribing"], ["minor changes in guidance for the use of influenza vaccines (e.g.,", "information licensed by the Food and Drug Administration"], ["guidance for timing of vaccination and other programmatic", "[FDA]). The summary included in the Background Document"], ["issues, guidance for dosage in specific populations, guidance", "for  such  topics  is  not  a  systematic  review;  it  is  intended"], ["for  selection  of  vaccines  for  specific  populations  that  are", "to  provide  an  overview  of  current  literature,  with  updated"], ["already  recommended  for  vaccination,  and  changes  that", "articles being identified primarily through a broad search for"]]}
{"id": "6adaae3c-e8e6-4303-9f72-3115fb58beb1", "page": 6, "type": "table", "data": [["", "Recommendations and Reports", ""], ["TABLE 2. Contraindications and precautions for the use of influenza vaccines \u2014 United States, 2022\u201323 influenza season*", "", ""], ["Vaccine type", "Contraindications", "Precautions"], ["Egg-based IIV4s", "\u2022 History of severe allergic reaction (e.g., anaphylaxis) to any", "\u2022 Moderate or severe acute illness with or without fever"], ["", "component of the vaccine\u2020 or to a previous dose of any influenza", "\u2022 History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of"], ["", "vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV)\u00a7", "influenza vaccine"], ["ccIIV4", "\u2022 History of severe allergic reaction (e.g., anaphylaxis) to a previous", "\u2022 Moderate or severe acute illness with or without fever"], ["", "dose of any ccIIV or any component of ccIIV4\u00a7", "\u2022 History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of"], ["", "", "influenza vaccine"], ["", "", "\u2022 History of severe allergic reaction to a previous dose of any other"], ["", "", "influenza vaccine (i.e., any egg-based IIV, RIV, or LAIV)\u00b6"], ["RIV4", "\u2022 History of severe allergic reaction (e.g., anaphylaxis) to a previous", "\u2022 Moderate or severe acute illness with or without fever"], ["", "dose of any RIV or any component of RIV4\u00a7", "\u2022 History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of"], ["", "", "influenza vaccine"], ["", "", "\u2022 History of severe allergic reaction to a previous dose of any other"], ["", "", "influenza vaccine (i.e., any egg-based IIV, ccIIV, or LAIV)\u00b6"], ["LAIV4", "\u2022 History of severe allergic reaction (e.g., anaphylaxis) to any", "\u2022 Moderate or severe acute illness with or without fever"], ["", "component of the vaccine\u2020 or to a previous dose of any influenza", "\u2022 History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of"], ["", "vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV)\u00a7", "influenza vaccine"], ["", "\u2022 Concomitant aspirin- or salicylate-containing therapy in children", "\u2022 Asthma in persons aged \u22655 years"], ["", "and adolescents\u00a7", "\u2022 Other underlying medical conditions that might predispose to"], ["", "\u2022 Children aged 2 through 4 years who have received a diagnosis of", "complications after wild-type influenza infection (e.g., chronic"], ["", "asthma or whose parents or caregivers report that a health care", "pulmonary, cardiovascular [except isolated hypertension], renal,"], ["", "provider has told them during the preceding 12 months that their", "hepatic, neurologic, hematologic, or metabolic disorders [including"], ["", "child had wheezing or asthma or whose medical record indicates a", "diabetes mellitus])"], ["", "wheezing episode has occurred during the preceding 12 months", ""], ["", "\u2022 Children and adults who are immunocompromised due to any cause,", ""], ["", "including but not limited to immunosuppression caused by", ""], ["", "medications, congenital or acquired immunodeficiency states, HIV", ""], ["", "infection, anatomic asplenia, or functional asplenia (e.g., due to sickle", ""], ["", "cell anemia)", ""], ["", "\u2022 Close contacts and caregivers of severely immunosuppressed persons", ""], ["", "who require a protected environment", ""], ["", "\u2022 Pregnancy", ""], ["", "\u2022 Persons with active communication between the CSF and the", ""], ["", "oropharynx, nasopharynx, nose, or ear or any other cranial CSF leak", ""], ["", "\u2022 Persons with cochlear implants**", ""], ["", "\u2022 Receipt of influenza antiviral medication within the previous 48 hours", ""], ["", "for oseltamivir and zanamivir, previous 5 days for peramivir, and", ""], ["", "previous 17 days for baloxavir\u2020\u2020", ""], ["", "Abbreviations: ACIP\u00a0=\u00a0Advisory Committee on Immunization Practices; ccIIV\u00a0=\u00a0cell culture\u2013based inactivated influenza vaccine (any valency); ccIIV4\u00a0=\u00a0cell culture\u2013", ""]]}
{"id": "c94dea9a-e44f-4b21-b2cf-eb72f6bab2e9", "page": 6, "type": "table", "data": [["Abbreviations: ACIP\u00a0=\u00a0Advisory Committee on Immunization Practices; ccIIV\u00a0=\u00a0cell culture\u2013based inactivated influenza vaccine (any valency); ccIIV4\u00a0=\u00a0cell culture\u2013"], ["based inactivated influenza vaccine, quadrivalent; CSF = cerebrospinal fluid; FDA = Food and Drug Administration; IIV\u00a0=\u00a0inactivated influenza vaccine (any valency);"], ["IIV4\u00a0=\u00a0inactivated influenza vaccine, quadrivalent; LAIV\u00a0=\u00a0live attenuated influenza vaccine (any valency); LAIV4\u00a0=\u00a0live attenuated influenza vaccine, quadrivalent;"], ["RIV\u00a0=\u00a0recombinant influenza vaccine (any valency); RIV4\u00a0=\u00a0recombinant influenza vaccine, quadrivalent."], ["* When a contraindication is present, a vaccine should not be administered. When a precaution is present, vaccination should generally be deferred but might be"], ["indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction (see ACIP General Best Practice Guidelines for Immunization,"], ["available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html). Vaccination providers should check FDA-approved prescribing information for"], ["2022\u201323 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions."], ["Package inserts for U.S.-licensed vaccines are available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states."], ["\u2020 Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV4s and LAIV4, ACIP recommends"], ["that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine that is otherwise appropriate for their age and health status."], ["Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema or swelling, respiratory distress, lightheadedness, or"], ["recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated in an inpatient or outpatient medical setting,"], ["including but not necessarily limited to hospitals, clinics, health departments, and physician offices, if a vaccine other than ccIIV4 or RIV4 is used. Vaccine administration"], ["should be supervised by a health care provider who is able to recognize and manage severe allergic reactions."], ["\u00a7 Labeled contraindication noted in package insert."], ["\u00b6  If administered, vaccination should occur in a medical setting and should be supervised by a health care provider who can recognize and manage severe allergic"], ["reactions. Providers can consider consultation with an allergist in such cases, to assist in identification of the component responsible for the allergic reaction."], ["** Age-appropriate injectable vaccines are recommended for persons with cochlear implant due to the potential for CSF leak, which might exist for a period after"], ["implantation. Providers might consider consultation with a specialist concerning risk for persistent CSF leak if an age-appropriate inactivated or recombinant"], ["vaccine cannot be used."], ["\u2020\u2020 Use of LAIV4 in context of influenza antivirals has not been studied; however, interference with activity of LAIV4 is biologically plausible, and this possibility is noted"], ["in the package insert for LAIV4. In the absence of data supporting an adequate minimum interval between influenza antiviral use and LAIV4 administration, the"], ["intervals provided are based on the half-life of each antiviral. The interval between influenza antiviral receipt and LAIV4 for which interference might potentially"], ["occur might be further prolonged in the presence of medical conditions that delay medication clearance (e.g., renal insufficiency). Influenza antivirals might also"], ["interfere with LAIV4 if initiated within 2 weeks after vaccination. Persons who receive antivirals during the period starting with the specified time before receipt"], ["of LAIV4 through 2 weeks after receipt of LAIV4 should be revaccinated with an age-appropriate IIV or RIV4."]]}
{"id": "6822485b-bdd0-4a16-91f7-0da4110072f7", "page": 7, "type": "table", "data": [["", "Recommendations and Reports", "", ""], ["TABLE 3. Influenza vaccine contraindications and precautions for persons with a history of severe allergic reaction to a previous dose of an", "", "", ""], ["influenza vaccine* \u2014 United States, 2022\u201323 influenza season", "", "", ""], ["Vaccine (of any valency) associated with", "", "Available 2022\u201323 influenza vaccines", ""], ["previous severe allergic reaction", "", "", ""], ["(e.g., anaphylaxis)", "Egg-based IIV4s and LAIV4", "ccIIV4", "RIV4"], ["Any egg-based IIV or LAIV", "Contraindication\u2020", "Precaution\u00a7", "Precaution\u00a7"], ["Any ccIIV", "Contraindication\u2020", "Contraindication\u2020", "Precaution\u00a7"], ["Any RIV", "Contraindication\u2020", "Precaution\u00a7", "Contraindication\u2020"], ["Unknown influenza vaccine", "", "Allergist consultation recommended", ""], ["", "Abbreviations: ACIP = Advisory Committee on Immunization Practices; ccIIV = cell culture\u2013based inactivated influenza vaccine (any valency); ccIIV4 = cell culture\u2013", "", ""], ["", "based inactivated influenza vaccine, quadrivalent; FDA = Food and Drug Administration; IIV = inactivated influenza vaccine (any valency); IIV4 = inactivated influenza", "", ""], ["", "vaccine, quadrivalent; LAIV = live attenuated influenza vaccine (any valency); LAIV4 = live attenuated influenza vaccine, quadrivalent; RIV = recombinant influenza", "", ""], ["vaccine (any valency); RIV4 = recombinant influenza vaccine, quadrivalent.", "", "", ""], ["*  Vaccination providers should check FDA-approved prescribing information for 2022\u201323 influenza vaccines for the most complete and updated information, including", "", "", ""], ["", "(but  not  limited  to)  indications,  contraindications,  warnings,  and  precautions.  Package  inserts  for  U.S.-licensed  vaccines  are  available  at https://www.fda.gov/", "", ""], ["vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.", "", "", ""], ["\u2020 When a contraindication is present, a vaccine should not be administered, consistent with ACIP General Best Practice Guidelines for Immunization (Kroger A, Bahta L,", "", "", ""], ["", "Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices [ACIP]. https://www.", "", ""], ["", "cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html). In addition to the contraindications based on history of severe allergic reaction to influenza vaccines that", "", ""], ["", "are noted in the table, each individual influenza vaccine is contraindicated for persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component", "", ""], ["", "of that vaccine. Vaccine components can be found in package inserts. Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication", "", ""], ["", "to the use of egg-based IIV4s and LAIV4, ACIP recommends that persons with a history of egg allergy may receive any licensed, recommended influenza vaccine", "", ""], ["", "that is otherwise appropriate for their age and health status. Those who report having had reactions to egg involving symptoms other than urticaria (e.g., angioedema", "", ""], ["", "or swelling, respiratory distress, lightheadedness, or recurrent emesis) or who required epinephrine or another emergency medical intervention should be vaccinated", "", ""], ["", "in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices), if a vaccine other", "", ""], ["", "than ccIIV4 or RIV4 is used. Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic reactions.", "", ""], ["\u00a7 When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for", "", "", ""], ["", "an adverse reaction, consistent with ACIP General Best Practice Guidelines for Immunization (Kroger A, Bahta L, Hunter P. General best practice guidelines for", "", ""], ["", "immunization: best practices guidance of the Advisory Committee on Immunization Practices [ACIP]. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/", "", ""], ["", "index.html). Providers can consider using the following vaccines in these instances; however, vaccination should occur in an inpatient or outpatient medical setting", "", ""], ["", "with supervision by a health care provider who is able to recognize and manage severe allergic reactions: 1) for persons with a history of severe allergic reaction", "", ""], ["", "(e.g., anaphylaxis) to any egg-based IIV or LAIV of any valency, the provider can consider administering ccIIV4 or RIV4; 2) for persons with a history of severe allergic", "", ""], ["", "reaction (e.g., anaphylaxis) to any ccIIV of any valency, the provider can consider administering RIV4; and 3) for persons with a history of severe allergic reaction (e.g.,", "", ""], ["", "anaphylaxis) to any RIV of any valency, the provider can consider administering ccIIV4. Providers can also consider consulting with an allergist to help determine", "", ""], ["which vaccine component is responsible for the allergic reaction.", "", "", ""]]}
{"id": "509a27aa-233f-454f-8552-7281ec3b8e3b", "page": 7, "type": "table", "data": [["", "reaction (e.g., anaphylaxis) to any ccIIV of any valency, the provider can consider administering RIV4; and 3) for persons with a history of severe allergic reaction (e.g.,"], ["", "anaphylaxis) to any RIV of any valency, the provider can consider administering ccIIV4. Providers can also consider consulting with an allergist to help determine"], ["which vaccine component is responsible for the allergic reaction.", ""], ["English-language articles on influenza and influenza vaccines.", "\u2022  Recommendations  for  the  composition  of  Northern"], ["Typically, systematic review and evaluation of evidence using", "Hemisphere influenza vaccines are made by the World Health"], ["the Grading of Recommendations Assessment, Development", "Organization (WHO), which organizes a consultation, usually"], ["and Evaluation (GRADE) approach (18) are performed for", "in February of each year. Surveillance data are reviewed, and"], ["new recommendations or substantial changes in the current", "candidate vaccine viruses are discussed. Information about the"], ["recommendations  (e.g.,  expansion  of  the  recommendation", "WHO meeting on February 25, 2022, for selection of the"], ["for influenza vaccination to new populations not previously", "2022\u201323 Northern Hemisphere vaccine viruses is available at"], ["recommended  for  vaccination  or  potential  preferential", "h t t p s : / / w w w. w h o. i n t / n e w s / i t e m / 2 5 - 0 2 - 2 0 2 2 -"], ["recommendations  for  specific  vaccines).  Systematic  review,", "recommendations-announced-for-influenza-vaccine-"], ["GRADE,  and  the  ACIP  Evidence  to  Recommendations", "composition-for-the-2022-2023-northern-hemisphere-"], ["Framework  were  used  in  the  development  of  the  updated", "influenza-season. Subsequently, FDA, which has regulatory"], ["recommendations  for  influenza  vaccination  of  adults  aged", "authority over vaccines in the United States, convenes a meeting"], ["\u226565 years discussed in this document.", "of  its Vaccines  and  Related  Biological  Products  Advisory"], ["Primary  updates  and  changes  to  the  recommendations", "Committee  (VRBPAC). This  committee  considers  the"], ["described  in  this  report  include  1)  the  vaccine  virus", "recommendations of WHO, reviews and discusses similar data,"], ["composition  for  2022\u201323  U.S.  seasonal  influenza  vaccines;", "and makes a final decision regarding vaccine virus composition"], ["2) updates to the description of influenza vaccines expected to", "of influenza vaccines licensed and marketed in the United"], ["be available for the 2022\u201323 season, including one influenza", "States. Materials from the VRBPAC discussion on March 3,"], ["vaccine  labeling  change  that  occurred  after  the  publication", "2022, during which the composition of the 2022\u201323 U.S."], ["of  the  2021\u201322  ACIP  influenza  recommendations;  and", "influenza vaccines was discussed, are available at https://www."], ["3) updates to the recommendations concerning vaccination of", "fda.gov/advisory-committees/advisory-committee-calendar/"], ["adults aged \u226565 years. Information relevant to these changes", "vaccines-and-related-biological-products-advisory-committee-"], ["includes the following:", "march-3-2022-meeting-announcement."]]}
{"id": "859a1572-7e9f-4d22-a6d3-bf34a2743344", "page": 8, "type": "table", "data": [["\u2022  Numerals following letter abbreviations indicate", "Routine  annual  influenza  vaccination  of  all  persons  aged"], ["valency (the number of influenza virus hemagglutinin", "\u22656 months who do not have contraindications continues to be"], ["[HA] antigens represented in the vaccine):", "recommended. Primary updates in this report include the following:"], ["\u0171", ""], ["4 for quadrivalent vaccines: one A(H1N1), one", "1.  The composition of the 2022\u201323 U.S. seasonal influenza"], ["A(H3N2), and two B viruses (one from each lineage)", "vaccines  includes  updates  to  the  influenza  A(H3N2)"], ["\u0171", ""], ["3 for trivalent vaccines: one A(H1N1), one", "and influenza B/Victoria components. For the 2022\u201323"], ["A(H3N2), and one B virus (from one lineage)", "season,  U.S.-licensed  influenza  vaccines  will  contain"], ["\u2022  All influenza vaccines expected to be available in the", "hemagglutinin  (HA)  derived  from  an  influenza"], ["United States for the 2022\u201323 season are quadrivalent", "A/Victoria/2570/2019 (H1N1)pdm09-like virus (for egg-"], ["vaccines. However, abbreviations for trivalent vaccines", "based vaccines) or an influenza A/Wisconsin/588/2019"], ["(e.g., IIV3) might be used in this report when", "(H1N1)pdm09-like  virus  (for  cell  culture\u2013based  and"], ["discussing information specific to trivalent vaccines.", "recombinant vaccines); an influenza A/Darwin/9/2021"], ["\u2022  Abbreviations for general vaccine categories (e.g., IIV)", "(H3N2)-like  virus  (for  egg-based  vaccines)  or  an"], ["might be used when discussing information that is not", "influenza A/Darwin/6/2021 (H3N2)-like virus (for cell"], ["specific to either trivalent or quadrivalent vaccines.", "culture\u2013based  or  recombinant  vaccines);  an  influenza"], ["\u2022  Prefixes are used when necessary to refer to certain", "B/Austria/1359417/2021  (Victoria  lineage)-like  virus;"], ["specific IIVs:", "and  an  influenza  B/Phuket/3073/2013  (Yamagata"], ["\u0171", ""], ["a for MF59-adjuvanted inactivated influenza", "lineage)-like virus."], ["vaccine (e.g., aIIV3 and aIIV4)", "2.  Influenza vaccines expected to be available for the 2022\u201323"], ["\u0171", ""], ["cc for cell culture\u2013based inactivated influenza", "season,  their  age  indications,  and  their  presentations  are"], ["vaccine (e.g., ccIIV3 and ccIIV4)", "described (Table 1). Afluria Quadrivalent is not expected"], ["\u0171 HD for high-dose inactivated influenza vaccine", "to be available in a 0.25-mL prefilled syringe presentation."], ["(e.g., HD-IIV3 and HD-IIV4)", "When  using  Afluria  Quadrivalent  for  children  aged"], ["\u0171", ""], ["SD for standard-dose inactivated influenza vaccine", "6 through 35 months (who require a 0.25-mL dose), the"], ["(e.g. SD-IIV3 and SD-IIV4)", "dose must be obtained from a multidose vial. One labeling"], ["", "change  is  described.  In  October  2021,  FDA  granted"], ["", "approval for the use of Flucelvax Quadrivalent (cell culture\u2013"], ["\u2022  Regarding recommendations concerning newly licensed", ""], ["", "based quadrivalent inactivated influenza vaccine [ccIIV4])"], ["influenza vaccines and changes to the licensed indications", ""], ["", "for children aged 6 months through <2 years. As of March"], ["for existing vaccines, ACIP relies on FDA for review of", ""], ["", "2021,  Flucelvax  Quadrivalent  had  been  approved  for"], ["safety, immunogenicity, and efficacy and effectiveness data", ""], ["", "persons aged \u22652 years. Approval for children aged 6 months"], ["pertaining to licensure and labeling of influenza vaccines.", ""], ["", "through <2 years was based on results of a randomized,"], ["Vaccines that are expected to be available for the 2022\u201323", ""], ["", "observer-blind study that compared immunogenicity and"], ["season  are  described  (see  Vaccines  Available  for  the", ""], ["", "safety  of  Flucelvax  Quadrivalent  with  that  of  a  licensed"], ["2022\u201323  Season)  (Table  1).  Regulatory  information", ""], ["", "comparator IIV4 among 2,402 children aged 6 through"], ["pertinent  to  the  change  in  age  indication  for  Flucelvax", ""], ["", "47 months, of whom 894 were aged 6 through 23 months."], ["Quadrivalent discussed in this report is available at https://", ""], ["", "Flucelvax Quadrivalent is now approved for persons aged"], ["www.fda.gov/vaccines-blood-biologics/vaccines/", ""], ["", "\u22656 months."], ["flucelvax-quadrivalent.", ""], ["", "3.  On the basis of review of evidence concerning high-dose"], ["\u2022  Regarding  updated  recommendations  for  influenza", ""], ["", "inactivated  influenza  vaccine  (HD-IIV),  recombinant"], ["vaccines for adults aged \u226565 years, a summary of the review", ""], ["", "influenza  vaccine  (RIV),  and  MF59-adjuvanted"], ["of evidence on this topic is available at https://www.cdc.", ""], ["", "inactivated influenza vaccine (aIIV), recommendations"], ["gov/vaccines/acip/recs/grade/influenza-older-adults.html.", ""], ["", "for  influenza  vaccination  of  persons  aged  \u226565  years"], ["A summary of the ACIP Evidence to Recommendations", ""]]}
{"id": "0da500e7-70af-4956-8221-d72b7c637b7f", "page": 9, "type": "table", "data": [["Recommendations and Reports", ""], ["have  been  modified.  ACIP  recommends  that  adults", "Considerations  for  timing  of  vaccination  include  the"], ["aged  \u226565  years  preferentially  receive  any  one  of  the", "following:"], ["following higher dose or adjuvanted influenza vaccines:", "\u2022  For  most  adults  (particularly  adults  aged  \u226565  years)"], ["quadrivalent  high-dose  inactivated  influenza  vaccine", "and  for  pregnant  persons  in  the  first  or  second"], ["(HD-IIV4), quadrivalent recombinant influenza vaccine", "trimester: Vaccination during July and August should be"], ["(RIV4), or quadrivalent adjuvanted inactivated influenza", "avoided unless there is concern that vaccination later in"], ["vaccine (aIIV4). If none of these three vaccines is available", "the season might not be possible."], ["at an opportunity for vaccine administration, then any", "\u2022  Children  who  require  2  doses:  Certain  children  aged"], ["other age-appropriate influenza vaccine should be used.", "6  months  through  8  years  require  2  doses  of  influenza"], ["Higher dose vaccines include HD-IIV4 and RIV4, both", "vaccine  for  the  season  (see  Children  Aged  6  Months"], ["of which contain a higher dose of HA antigen per virus", "Through 8 Years: Number of Influenza Vaccine Doses)"], ["than standard-dose vaccines (60 \u00b5g for HD-IIV4 and", "(Figure). These children should receive their first dose as"], ["45 \u00b5g for RIV4, compared with 15 \u00b5g for standard-dose", "soon  as  possible  (including  during  July  and  August,  if"], ["inactivated vaccines). Adjuvanted inactivated influenza", "vaccine is available) to allow the second dose (which must"], ["vaccine (aIIV4) contains MF59 adjuvant.", "be administered \u22654 weeks later) to be received, ideally, by"], ["", "the end of October."], ["", "\u2022  Children who require only 1 dose: Vaccination during"], ["Recommendations for the Use of", "July and August can be considered for children of any age"], ["", "who need only 1 dose of influenza vaccine for the season."], ["Influenza Vaccines, 2022\u201323", ""], ["", "While  waning  of  immunity  after  vaccination  over  the"], ["", "course  of  the  season  has  been  observed  among  all  age"], ["Groups Recommended for Vaccination", ""], ["", "groups (19\u201332), there are fewer published studies reporting"], ["Routine annual influenza vaccination is recommended for all", ""], ["", "results  specifically  among  children  (19\u201322).  Moreover,"], ["persons aged \u22656 months who do not have contraindications.", ""], ["", "children in this group might visit health care providers"], ["Recommendations  regarding  timing  of  vaccination,", ""], ["", "during the late summer months for medical examinations"], ["considerations  for  specific  populations,  the  use  of  specific", ""], ["", "before the start of school. Vaccination can be considered"], ["vaccines, and contraindications and precautions are summarized", ""], ["", "at this time because it represents a vaccination opportunity."], ["in the sections that follow.", ""], ["", "\u2022  Pregnant  persons  in  the  third  trimester:  Vaccination"], ["", "during July and August can be considered for pregnant"], ["Timing of Vaccination", ""], ["", "persons who are in the third trimester because vaccination"], ["Because timing of the onset, peak, and decline of influenza", "might  reduce  risk  for  influenza  illness  in  their  infants"], ["activity varies, the ideal time to start vaccinating cannot be", "during  the  first  months  after  birth,  when  they  are  too"], ["predicted  each  season.  Decisions  about  timing  necessitate", "young to receive influenza vaccine (33\u201336). For pregnant"], ["balancing  considerations  regarding  this  unpredictability  of", "persons in the first or second trimester during July and"], ["the  influenza  season,  possible  waning  of  vaccine-induced", "August, waiting to vaccinate until September or October"], ["immunity  over  the  course  of  a  season,  and  programmatic", "is preferable, unless there is concern that later vaccination"], ["considerations. Influenza vaccines might be available as early", "might not be possible."], ["as July or August; however, vaccination during these months", "Community  vaccination  programs  should  balance"], ["is not recommended for most groups because of the possible", "maximizing the likelihood of persistence of vaccine-induced"], ["waning of immunity over the course of the influenza season", "protection  through  the  season  with  avoiding  missed"], ["(19\u201332). For most persons who need only 1 dose of influenza", "opportunities  to  vaccinate  or  vaccinating  after  onset  of"], ["vaccine for the season, vaccination should ideally be offered", "influenza circulation occurs. Efforts should be structured to"], ["during September or October. However, vaccination should", "optimize vaccination coverage before influenza activity in the"], ["continue after October and throughout the influenza season as", "community begins. Vaccination should continue to be offered"], ["long as influenza viruses are circulating and unexpired vaccine", "as  long  as  influenza  viruses  are  circulating  and  unexpired"], ["is available.", "vaccine  is  available.  To  avoid  missed  opportunities  for"]]}
{"id": "6022d6e4-481b-4883-845a-fd78a7f2510b", "page": 10, "type": "table", "data": [["", "Recommendations and Reports", ""], ["", "FIGURE.  Influenza  vaccine  dosing  algorithm  for  children  aged", ""], ["", "", "However, in 29 (76%) of 38 influenza seasons from 1982\u201383"], ["", "6 months through 8 years* \u2014 Advisory Committee on Immunization", ""], ["", "", "through 2019\u201320, peak influenza activity (which often is close"], ["", "Practices, United States, 2022\u201323 influenza season", ""], ["Support Width Options", "", "to the midpoint of influenza activity for the season) has not"], ["Page wide =  7.5\u201d", "", ""], ["", "", "occurred until January or later, and in 23 (61%) seasons, the"], ["QuickStats = 5.0\u201d", "Did the child receive \u22652 doses of", ""], ["1\u00bd columns = 4.65\u201d", "", "peak was in February or later (37). Activity peaked in February"], ["", "trivalent or quadrivalent influenza vaccine", ""], ["1 column = 3.57\u201d", "", ""], ["", "before July 1, 2022?", "in 17 (45%) of these seasons (37)."], ["", "(Doses need not have been received", ""], ["", "", "An increasing number of observational studies (19\u201332) have"], ["", "during same or consecutive seasons.)", ""], ["", "", "reported  decreases  in  vaccine  effectiveness  with  increasing"], ["", "", "time postvaccination within a single influenza season. Waning"], ["", "", "effects have not been observed consistently across age groups,"], ["", "No or unknown\nYes", "influenza viruses (types, subtypes, and lineages), or seasons."], ["", "", "Certain  studies  suggest  waning  occurs  to  a  greater  degree"], ["", "", "against  influenza  A(H3N2)  viruses  than  against  influenza"], ["", "", "A(H1N1)  or  influenza  B  viruses  (26,27). This  effect  also"], ["", "1 dose of\n2 doses of", ""], ["", "", "might  vary  with  recipient  age;  in  certain  studies,  waning"], ["", "2022\u201323\n2022\u201323", ""], ["", "", "was more pronounced among older adults (19,23,26,30,32)"], ["", "influenza vaccine\ninfluenza vaccine", ""], ["", "(administered", "and younger children (19). Relatively fewer reports include"], ["", "\u22654 weeks apart)", ""], ["", "", "results  specific  to  children  (19\u201322);  findings  suggestive  of"], ["", "", "waning  have  been  reported  in  certain  studies  (19\u201321)  but"], ["", "* Children aged 6 months through 8 years who require 2 doses of influenza", "not others (22). Rates of decline in vaccine effectiveness also"], ["", "vaccine should receive their first dose as soon as possible (including during", ""], ["", "", "varied. A multiseason (2011\u201312 through 2014\u201315) analysis"], ["", "July and August, if vaccine is available) to allow the second dose (which must", ""], ["", "be administered \u22654 weeks later) to be received, ideally, by the end of October.", "from  the  U.S.  Influenza  Vaccine  Effectiveness  (U.S.  Flu"], ["", "For children aged 8 years who require 2 doses of vaccine, both doses should", ""], ["", "", "VE) Network found that vaccine effectiveness decreased by"], ["", "be administered even if the child turns age 9 years between receipt of dose 1", ""], ["", "", "approximately  7%  per  month  for  influenza  A(H3N2)  and"], ["", "and dose 2.", ""], ["", "", "influenza B and 6%\u201311% per month for influenza A(H1N1)"], ["", "vaccination, providers should offer vaccination during routine", "pdm09 (25). Vaccine effectiveness remained greater than zero"], ["", "health care visits and hospitalizations. No recommendation is", "for at least 5\u20136 months after vaccination. In the Hospitalized"], ["", "made for revaccination (i.e., providing a booster dose) later", "Adult  Influenza  Vaccine  Effectiveness  Network  (HAIVEN)"], ["", "in the season of persons who have been fully vaccinated for", "during  the  2015\u201316  through  2018\u201319  seasons,  vaccine"], ["", "the  season,  regardless  of  when  the  current  season  vaccine", "effectiveness  against  influenza-associated  hospitalizations"], ["", "was received.", "declined by approximately 8%\u20139% per month for all adults"], ["", "During  the  2022\u201323  influenza  season,  SARS-CoV-2", "and  approximately  10%\u201311%  per  month  for  those  aged"], ["", "is  expected  to  continue  to  circulate  in  the  United  States,", "\u226565 years (32). An analysis of the 2010\u201311 through 2013\u201314"], ["", "and  COVID-19  vaccinations  are  expected  to  continue.", "seasons  noted  estimated  effectiveness  ranging  from  54%  to"], ["", "Current  guidance  for  the  administration  of  COVID-19", "67% during days 0\u2013180 postvaccination; estimated vaccine"], ["", "vaccines  (\u201cCoadministration  of  COVID-19  vaccines", "effectiveness  was  not  significant  during  the  period  between"], ["", "with  other  vaccines\u201d  at  https://www.cdc.gov/vaccines/", "days 181 and 365 (20). A third multiseason analysis (2010\u201311"], ["", "covid-19/clinical-considerations/interim-considerations-us.", "through  2014\u201315)  conducted  in  Europe  noted  a  decline"], ["", "html#recommendations) indicates that these vaccines can be", "in  vaccine  effectiveness  to  0%  at  111  days  postvaccination"], ["", "administered with influenza vaccines; providers should consult", "against  influenza  A(H3N2)  viruses.  Vaccine  effectiveness"], ["", "this  page  for  updated  information.  Guidance  for  vaccine", "against influenza B viruses decreased more slowly, and vaccine"], ["", "planning  during  the  COVID-19  pandemic  is  available  at", "effectiveness  against  influenza  A(H1N1)pdm09  viruses"], ["", "https://www.cdc.gov/vaccines/pandemic-guidance/index.html.", "remained roughly stable at 50%\u201355% throughout the influenza"], ["", "Optimally, vaccination should occur before onset of influenza", "season (27). A meta-analysis of 14 studies examining waning"], ["", "activity in the community. However, because timing of the onset,", "of influenza vaccine effectiveness using the test-negative design"], ["", "peak, and decline of influenza activity varies, the ideal time to", "found a significant decline in effectiveness within 180 days"], ["", "start vaccinating cannot be predicted each season. Moreover,", "after vaccination against influenza A (H3N2) and influenza B"], ["", "more than one outbreak might occur in a community in a single", "but not against influenza A(H1N1) (38). In addition to the"], ["", "year. In  the  United States, localized outbreaks indicating the", "factors observed to be associated with waning immunity across"], ["", "start of seasonal influenza activity can occur as early as October.", "studies, observed decreases in protection might be at least in"]]}
{"id": "34638925-64fa-4146-a85e-e97e3fb6e8bb", "page": 11, "type": "table", "data": [["Recommendations and Reports", ""], ["part  attributable  to  bias,  unmeasured  confounding,  or  the", "efforts should focus on vaccination of persons at higher risk for"], ["late-season emergence of antigenic drift variants of influenza", "medical complications attributable to severe influenza who do"], ["viruses that are less well-matched to the vaccine viruses.", "not have contraindications. These persons include the following"], ["Varying data concerning the presence and rate of waning", "(no hierarchy is implied by order of listing):"], ["immunity  after  influenza  vaccination,  coupled  with  the", "\u2022  All children aged 6 through 59 months."], ["unpredictable timing of the influenza season each year, prevent", "\u2022  All persons aged \u226550 years."], ["determination of an optimal time to vaccinate. Programmatic", "\u2022  Adults  and  children  who  have  chronic  pulmonary"], ["issues also are a consideration. Although delaying vaccination", "(including  asthma),  cardiovascular  (excluding  isolated"], ["might result in greater immunity later in the season, deferral", "hypertension), renal, hepatic, neurologic, hematologic, or"], ["also  might  result  in  missed  opportunities  to  vaccinate  as", "metabolic disorders (including diabetes mellitus)."], ["well as difficulties in vaccinating a population within a more", "\u2022  Persons who are immunocompromised due to any cause"], ["constrained period. The potential contributions of these factors", "(including but not limited to immunosuppression caused"], ["among  persons  aged  \u226565  years  have  been  assessed  using  a", "by medications or HIV infection)."], ["simulated  mathematical  model  examining  various  scenarios", "\u2022  Persons who are or will be pregnant during the influenza season."], ["of vaccination timing, timing of onset of the influenza season,", "\u2022  Children  and  adolescents  (aged  6  months  through"], ["vaccine effectiveness, and rate of waning (39). In this model,", "18 years) who are receiving aspirin- or salicylate-containing"], ["during an influenza season beginning in October and peaking", "medications and who might be at risk for experiencing"], ["in  January,  delaying  vaccination  until  October  resulted  in", "Reye syndrome after influenza virus infection."], ["more hospitalizations if >14% of persons aged \u226565 years who", "\u2022  Residents  of  nursing  homes  and  other  long-term  care"], ["would have been vaccinated in August or September failed to", "facilities."], ["get vaccinated. However, these predictions varied considerably", "\u2022  American Indian or Alaska Native persons."], ["with assumed timing of season onset, rate of waning immunity,", "\u2022  Persons who are extremely obese (body mass index \u226540"], ["and vaccine effectiveness.", "for adults)."], ["Vaccination efforts should continue throughout the season", "An  IIV4  or  RIV4  (as  appropriate  for  the  recipient\u2019s  age)"], ["because  the  duration  of  the  influenza  season  varies,  and", "is  suitable  for  persons  in  all  risk  groups.  LAIV4  is  not"], ["influenza  activity  might  not  occur  in  certain  communities", "recommended  for  certain  populations,  including  certain  of"], ["until February, March, or later. Providers should offer influenza", "these listed groups. Contraindications and precautions for the"], ["vaccine routinely, and organized vaccination campaigns should", "use of LAIV4 are noted (Tables 2 and 3)."], ["continue  throughout  the  influenza  season,  including  after", ""], ["", "Persons Who Live with or Care for Persons at"], ["influenza  activity  has  begun  in  the  community.  Although", ""], ["", "Higher Risk for Influenza-Related Complications"], ["vaccination by the end of October is recommended, vaccine", ""], ["administered in December or later, even if influenza activity has", "All  persons  aged  \u22656  months  without  contraindications"], ["already begun, might be beneficial in most influenza seasons.", "should be vaccinated annually. However, emphasis also should"], ["Providers should offer influenza vaccination to unvaccinated", "be placed on vaccination of persons who live with or care for"], ["persons who have already become ill with influenza during the", "those  who  are  at  increased  risk  for  medical  complications"], ["season because the vaccine might protect them against other", "attributable  to  severe  influenza.  When  vaccine  supply  is"], ["circulating influenza viruses.", "limited,  vaccination  efforts  should  focus  on  administering"], ["", "vaccination  to  persons  at  higher  risk  for  influenza-related"]]}
{"id": "7490acc2-b1e6-46b0-80ec-f52aa67a5f56", "page": 12, "type": "table", "data": [["Recommendations and Reports", ""], ["agents (e.g., clerical, dietary, housekeeping, laundry, security,", "Children Aged 6 Through 35 Months: Influenza"], ["maintenance, administrative, and billing staff persons and", "Vaccine Dose Volumes"], ["volunteers). ACIP guidance for vaccination of health care", ""], ["", "Five IIV4s are approved for children aged \u22656 months (Table 1)."], ["personnel has been published previously (40).", ""], ["", "Four  of  these  vaccines  are  egg  based  (Afluria  Quadrivalent,"], ["\u2022  Household contacts (including children aged \u22656 months)", ""], ["", "Fluarix  Quadrivalent,  Flulaval  Quadrivalent,  and  Fluzone"], ["and caregivers of children aged \u226459 months (<5 years) and", ""], ["", "Quadrivalent),  and  one  is  cell  culture  based  (Flucelvax"], ["adults  aged  \u226550  years,  particularly  contacts  of  children", ""], ["", "Quadrivalent). For these vaccines, the approved dose volumes"], ["aged <6 months.", ""], ["", "for children aged 6 through 35 months are as follows (Table 4):"], ["\u2022  Household contacts (including children aged \u22656 months)", ""], ["", "\u2022  Afluria Quadrivalent: 0.25 mL per dose. However, 0.25-mL"], ["and caregivers of persons with medical conditions that put", ""], ["", "prefilled  syringes  are  not  expected  to  be  available  for  the"], ["them at higher risk for severe complications from influenza.", ""], ["", "2022\u201323 season. For children aged 6 through 35 months, a"], ["Health  care  personnel  and  persons  who  are  contacts  of", ""]]}
{"id": "662e5a85-acc9-46fc-89f2-d0db8e4356a9", "page": 12, "type": "table", "data": [["", "for children aged 6 through 35 months are as follows (Table 4):"], ["\u2022  Household contacts (including children aged \u22656 months)", ""], ["", "\u2022  Afluria Quadrivalent: 0.25 mL per dose. However, 0.25-mL"], ["and caregivers of persons with medical conditions that put", ""], ["", "prefilled  syringes  are  not  expected  to  be  available  for  the"], ["them at higher risk for severe complications from influenza.", ""], ["", "2022\u201323 season. For children aged 6 through 35 months, a"], ["Health  care  personnel  and  persons  who  are  contacts  of", ""], ["", "0.25-mL dose must be obtained from a multidose vial (43)."], ["persons  in  these  groups  (with  the  exception  of  contacts  of", ""], ["", "\u2022  Fluarix Quadrivalent: 0.5 mL per dose."], ["severely immunocompromised persons who require a protected", ""], ["", "\u2022  Flucelvax Quadrivalent: 0.5 mL per dose."], ["environment) may receive any influenza vaccine that is otherwise", ""], ["", "\u2022  FluLaval Quadrivalent: 0.5 mL per dose."], ["indicated. Persons who care for severely immunocompromised", ""], ["", "\u2022  Fluzone Quadrivalent: either 0.25 mL or 0.5 mL per dose."], ["persons requiring a protected environment should not receive", ""], ["", "Per the package insert, each dose may be given at either"], ["LAIV4. ACIP and the Healthcare Infection Control Practices", ""], ["", "volume (44); however, the 0.25-mL prefilled syringes are"], ["Advisory Committee (HICPAC) have previously recommended", ""], ["", "no longer available."], ["that  health  care  personnel  who  receive  LAIV  should  avoid", ""], ["", "For all of these IIV4s, persons aged \u226536 months (\u22653 years)"], ["providing  care  for  severely  immunocompromised  persons", ""], ["", "should receive 0.5 mL per dose."], ["requiring a protected environment for 7 days after vaccination", ""], ["", "Alternatively,  healthy  children  aged  \u226524  months  (\u22652  years)"], ["and that hospital visitors who have received LAIV should avoid", ""], ["", "may receive LAIV4, 0.2 mL intranasally (0.1 mL in each nostril)."], ["contact  with  such  persons  for  7  days  after  vaccination  (41).", ""], ["", "LAIV4 is not recommended for certain populations and is not"], ["However, such persons need not be restricted from caring for", ""], ["", "approved for children aged <2 years (see Contraindications and"], ["or visiting less severely immunocompromised persons.", ""], ["", "Precautions for the Use of LAIV4) (Table 2). RIV4 is not approved"], ["Influenza Vaccination of Persons with COVID-19", "for  children  aged  <18  years.  High-dose  inactivated  influenza"], ["", "vaccine (HD-IIV4) and adjuvanted inactivated influenza vaccine"], ["Vaccination of persons who have tested positive for COVID-19", ""], ["", "(aIIV4) are not approved for persons aged <65 years."], ["or  who  are  in  quarantine  after  an  exposure  should  include", ""], ["", "Care should be taken to administer an age-appropriate vaccine at"], ["multiple  considerations,  such  as  whether  bringing  the  person", ""], ["", "the appropriate volume for each dose. For IIV4s, the recommended"], ["into a vaccination setting could expose others to COVID-19,", ""], ["", "volume may be administered from a prefilled syringe containing the"], ["whether the person is acutely ill and the severity of the illness, the", ""], ["", "appropriate volume (as supplied by the manufacturer), a single-dose"], ["presence of risk factors for severe influenza illness, the likelihood", ""], ["", "vial, or a multidose vial. Single-dose vials should be used for only"], ["of being able to vaccinate at a later date, and the desire to avoid", ""], ["", "1 dose, and multidose vials should be used only for the maximum"], ["confusing postvaccination symptoms with those of COVID-19.", ""], ["", "number  of  doses  specified  in  the  package  insert.  Any  vaccine"], ["Usually, persons who are in quarantine or isolation should not be", ""], ["", "remaining in a vial after the maximum number of doses has been"], ["brought to a vaccination setting if doing so could expose others to", ""], ["", "removed should be discarded, regardless of the volume of the doses"], ["COVID-19. For those who have moderate or severe COVID-19,", ""], ["", "obtained or any remaining volume in the vial."], ["vaccination should usually be deferred until they have recovered,", ""], ["which is consistent with ACIP General Best Practice Guidelines for", "Children Aged 6 Months Through 8 Years:"], ["Immunization (42). For persons who have mild or asymptomatic", ""], ["", "Number of Influenza Vaccine Doses"], ["COVID-19,  further  deferral  might  be  considered  to  avoid", ""], ["", "Children aged 6 months through 8 years require 2 doses of"], ["confusing COVID-19 symptoms with postvaccination reactions.", ""], ["", "influenza vaccine administered a minimum of 4 weeks apart"], ["Because  recommendations  for  vaccination  of  this  population", ""], ["", "during their first season of vaccination for optimal protection"], ["might continue to evolve, clinicians should check CDC guidance", ""], ["", "(45\u201348).  Determination  of  the  number  of  doses  needed  is"], ["(https://www.cdc.gov/vaccines/pandemic-guidance/index.html)", ""], ["", "based  on  1)  the  child\u2019s  age  at  the  time  of  the  first  dose  of"], ["for up-to-date information.", ""], ["", "2022\u201323  influenza  vaccine  and  2)  the  number  of  doses  of"]]}
{"id": "3b11cd6c-7973-4af9-9d94-6eefd96375ff", "page": 13, "type": "table", "data": [["\u2022  For children aged 6 months through 8 years, the number"], ["of  doses  of  influenza  vaccine  needed  for  the  2022\u201323"], ["influenza season is determined as follows (Figure):"], ["\u0171 Those  who  have  previously  received  \u22652  total  doses  of"], ["trivalent or quadrivalent influenza vaccine \u22654 weeks apart"], ["before July 1, 2022, require only 1 dose for the 2022\u201323"], ["season. The 2 previous doses of influenza vaccine do not"], ["need  to  have  been  received  in  the  same  season  or"], ["consecutive seasons."], ["\u0171 Those  who  have  not  previously  received  \u22652  doses  of"], ["trivalent  or  quadrivalent  influenza  vaccine  \u22654  weeks"], ["apart before July 1, 2022, or whose previous influenza"], ["vaccination history is unknown, require 2 doses for the"], ["2022\u201323  season. The  interval  between  the  2  doses"], ["should be \u22654 weeks. Children aged 6 months through"], ["8 years who require 2 doses of influenza vaccine should"], ["receive  their  first  dose  as  soon  as  possible  (including"], ["during July and August, if vaccine is available) to allow"], ["the second dose (which must be administered \u22654 weeks"], ["later)  to  be  received,  ideally,  by  the  end  of  October."], ["Two doses are recommended even if the child turns age"], ["9 years between receipt of dose 1 and dose 2."], ["\u2022  Adults and children aged \u22659 years need only 1 dose of"]]}
{"id": "4b8d3a68-1898-4aa4-be55-111d7054d3be", "page": 13, "type": "table", "data": [["Recommendations and Reports", ""], ["TABLE 4. Dose volumes for inactivated influenza vaccines approved", ""], ["", "Pregnant Persons"], ["for children aged 6 through 35 months* \u2014 United States, 2022\u201323", ""], ["influenza season", "Pregnant and postpartum persons have been observed to be at"], ["Dose volume for children", "higher risk for severe illness and complications from influenza,"], ["aged 6 through 35 mos", ""], ["", "particularly during the second and third trimesters. Influenza"], ["Trade name (Manufacturer)\n(\u00b5g HA per vaccine virus)", ""], ["", "vaccination during pregnancy is associated with reduced risk"], ["Afluria Quadrivalent (Seqirus)\n0.25 mL (7.5 \u00b5g)\u2020", ""], ["", "for  respiratory  illness  and  influenza  among  pregnant  and"], ["Fluarix Quadrivalent \n0.5 mL (15 \u00b5g)", ""], ["(GlaxoSmithKline)", "postpartum persons as well as infants during the first several"], ["Flucelvax Quadrivalent (Seqirus)\n0.5 mL (15 \u00b5g)", ""], ["", "months of life (33\u201336,49). ACIP and the American College"], ["FluLaval Quadrivalent \n0.5 mL (15 \u00b5g)", ""], ["(GlaxoSmithKline)", "of Obstetricians and Gynecologists recommend that persons"], ["Fluzone Quadrivalent (Sanofi \n 0.5 mL (15 \u00b5g)\u00a7", "who are pregnant or who might be pregnant or postpartum"], ["Pasteur)", ""], ["", "during the influenza season receive influenza vaccine (50). Any"], ["Abbreviation: HA = hemagglutinin.", ""], ["", "licensed, recommended, and age-appropriate IIV4 or RIV4"], ["* For persons aged \u226536 months (\u22653 years), the dose volume is 0.5 mL per dose", ""], ["for all inactivated influenza vaccines with the exception of Fluzone High-Dose", "may be used. LAIV4 should not be used during pregnancy but"], ["Quadrivalent (HD-IIV4), which is licensed for persons aged \u226565 years and for", ""], ["", "can be used postpartum. Influenza vaccine can be administered"], ["which the dose volume is 0.7 mL per dose.", ""], ["", "at any time during pregnancy (i.e., during any trimester), before"], ["\u2020 The approved dose volume for Afluria Quadrivalent is 0.25 mL for children aged", ""], ["6 through 35 months and 0.5 mL for persons aged \u22653 years. However, 0.25-mL", "and during the influenza season. Early vaccination (i.e., during"], ["prefilled syringes are not expected to be available for the 2022\u201323 season. For", ""], ["", "July  and  August)  can  be  considered  for  persons  who  are  in"], ["children aged 6 through 35 months, a 0.25-mL dose must be obtained from a", ""], ["multidose vial.", "the third trimester during these months if vaccine is available"], ["\u00a7 Per the package insert, Fluzone Quadrivalent is currently approved for children", ""], ["", "because this can provide protection for the infant during the"], ["aged 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL", ""], ["prefilled  syringes  are  no  longer  available.  If  a  prefilled  syringe  of  Fluzone", "first months of life when they are too young to be vaccinated."], ["Quadrivalent is used for a child in this age group, the dose volume will be 0.5 mL", ""], ["", "Although experience with the use of IIVs during pregnancy"], ["per dose. The 0.5-mL single-dose vials should be accessed for only 1 dose and", ""], ["multidose vials for only 10 doses, regardless of the volume of the doses obtained", "is  substantial,  data  specifically  reflecting  administration  of"], ["or any remaining volume in the vial. Any vaccine remaining in a vial after the", ""], ["", "influenza  vaccines  during  the  first  trimester  are  limited  (see"], ["maximum number of doses has been removed should be discarded.", ""], ["", "Safety of Influenza Vaccines in the supplementary Background"], ["", "Document). Most studies have not noted an association between"], ["\u2022  For children aged 6 months through 8 years, the number", ""], ["", "influenza vaccination and adverse pregnancy outcomes, including"], ["of  doses  of  influenza  vaccine  needed  for  the  2022\u201323", ""], ["", "spontaneous abortion (miscarriage) (51\u201361). One observational"], ["influenza season is determined as follows (Figure):", ""], ["", "Vaccine  Safety  Datalink  (VSD)  study  conducted  during  the"], ["\u0171 Those  who  have  previously  received  \u22652  total  doses  of", ""], ["", "2010\u201311  and  2011\u201312  seasons  noted  an  association  between"], ["trivalent or quadrivalent influenza vaccine \u22654 weeks apart", ""], ["", "receipt  of  IIV  containing  influenza  A(H1N1)pdm09  and  risk"], ["before July 1, 2022, require only 1 dose for the 2022\u201323", ""], ["", "for  miscarriage  in  the  28  days  after  receipt  of  IIV,  when  an"], ["season. The 2 previous doses of influenza vaccine do not", ""], ["", "H1N1pdm09-containing  vaccine  also  had  been  received  the"], ["need  to  have  been  received  in  the  same  season  or", ""], ["", "previous season (62). However, in a larger VSD follow-up study,"], ["consecutive seasons.", ""], ["", "IIV  was  not  associated  with  an  increased  risk  for  miscarriage"], ["\u0171 Those  who  have  not  previously  received  \u22652  doses  of", ""], ["", "during the 2012\u201313, 2013\u201314, and 2014\u201315 seasons, regardless"], ["trivalent  or  quadrivalent  influenza  vaccine  \u22654  weeks", ""], ["", "of previous season vaccination (63)."], ["apart before July 1, 2022, or whose previous influenza", ""], ["", "Substantially less experience exists with more recently licensed"], ["vaccination history is unknown, require 2 doses for the", ""], ["", "IIVs (e.g., quadrivalent and cell culture\u2013based vaccines) during"], ["2022\u201323  season. The  interval  between  the  2  doses", ""], ["", "pregnancy  than  with  previously  available  products.  For  RIV"], ["should be \u22654 weeks. Children aged 6 months through", ""], ["", "(available  as  RIV3  from  2013\u201314  through  2017\u201318  and  as"], ["8 years who require 2 doses of influenza vaccine should", ""], ["", "RIV4 since 2017\u201318), data are limited to reports of pregnancies"], ["receive  their  first  dose  as  soon  as  possible  (including", ""], ["", "occurring incidentally during clinical trials, Vaccine Adverse Event"], ["during July and August, if vaccine is available) to allow", ""], ["", "Reporting  System  (VAERS)  reports,  and  pregnancy  registries."], ["the second dose (which must be administered \u22654 weeks", ""], ["", "Pregnancy  registries  and  surveillance  studies  exist  for  certain"], ["later)  to  be  received,  ideally,  by  the  end  of  October.", ""], ["", "products, for which information can be found in package inserts."], ["Two doses are recommended even if the child turns age", ""], ["9 years between receipt of dose 1 and dose 2.", ""], ["", "Older Adults"], ["\u2022  Adults and children aged \u22659 years need only 1 dose of", ""], ["", "ACIP recommends that adults aged \u226565 years preferentially"], ["influenza vaccine for the 2022\u201323 season.", ""], ["", "receive  any  one  of  the  following  higher  dose  or  adjuvanted"]]}
{"id": "254e736d-1b99-4ac3-bd18-102159ded632", "page": 14, "type": "table", "data": [["Recommendations and Reports", ""], ["influenza vaccines: quadrivalent high-dose inactivated influenza", "Randomized Studies Comparing HD-IIV, RIV, and aIIV"], ["vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine", "with  Nonadjuvanted  SD-IIVs:  Prevention  of  Influenza"], ["(RIV4),  or  quadrivalent  adjuvanted  inactivated  influenza", "Illnesses.  Randomized  studies  comparing  HD-IIV,  RIV,"], ["vaccine (aIIV4). If none of these three vaccines is available at", "and  aIIV  with  nonadjuvanted  SD-IIVs  against  laboratory-"], ["an opportunity for vaccine administration, then any other age-", "confirmed  influenza  illness  are  few  in  number  and  were"], ["appropriate influenza vaccine should be administered.", "conducted  over  few  influenza  seasons.  HD-IIV3  was  more"], ["Older adults (aged \u226565 years) are at increased risk for severe", "effective  than  SD-IIV3  in  prevention  of  polymerase  chain"], ["influenza-associated illness, hospitalization, and death compared", "reaction  (PCR)-  or  culture-confirmed  influenza-like  illness"], ["with younger persons (4,16,64). Influenza vaccines are often less", "(ILI)  in  a  two-season  randomized  study  conducted  among"], ["effective in this population (65). HD-IIV, RIV, and aIIV have", "32,000  persons  aged  \u226565  years  (relative  efficacy:  24%;"], ["been evaluated in comparison with nonadjuvanted SD-IIVs in", "95% CI: 10%\u201336%; certainty level: 1, high) (66). Two single-"], ["this age group. Two of these vaccines, HD-IIV and RIV, are", "season randomized trials of RIV versus nonadjuvanted SD-IIV,"], ["higher dose vaccines, which contain an increased dose of HA", "one a comparison of RIV3 versus nonadjuvanted SD-IIV3 that"], ["antigen per virus compared with nonadjuvanted SD-IIVs (60 \u00b5g", "assessed culture-confirmed ILI (67) and the other a comparison"], ["for HD-IIV4 and 45 \u00b5g for RIV4, compared with 15 \u00b5g for", "of RIV4 versus nonadjuvanted SD-IIV4 that examined PCR-"], ["standard-dose  inactivated  vaccines). The  adjuvanted  vaccine", "confirmed ILI (68), did not demonstrate relative benefit of"], ["contains  15  \u00b5g  of  HA  per  virus,  similarly  to  nonadjuvanted", "RIV  among  those  aged  \u226565  years  (pooled  relative  efficacy:"], ["SD-IIVs, but contains the adjuvant MF59.", "18%; 95% CI: \u221217% to 43%; certainty level: 2, moderate)."], ["HD-IIV, RIV, and aIIV have shown relative benefit compared", "The larger of these two studies noted a relative benefit of RIV4"], ["with SD-IIVs in certain studies, with the most evidence available", "over nonadjuvanted SD-IIV4 in prevention of PCR-confirmed"], ["for  HD-IIV3.  Randomized  efficacy  studies  comparing  these", "influenza  among  the  full  study  population  of  persons  aged"], ["vaccines  with  nonadjuvanted  SD-IIVs  against  laboratory-", "\u226550 years (relative efficacy: 30%; 95% CI: 10%\u201347%) as well"], ["confirmed influenza outcomes are few in number (66\u201368) and", "as against culture-confirmed ILI among those aged \u226565 years"], ["cover few influenza seasons. Observational studies, predominantly", "(relative efficacy: 42%; 95% CI: 9%\u201365%) (68). No data are"], ["retrospective cohort studies using diagnostic code\u2013defined (rather", "available from randomized trials of aIIV versus nonadjuvanted"], ["than laboratory-confirmed) outcomes, are more numerous and", "SD-IIVs  against  laboratory-confirmed  influenza  outcomes"], ["include more influenza seasons (69\u201379). Certain observational", "during nonpandemic influenza seasons."], ["studies have reported relative benefit for HD-IIV, RIV, and aIIV", ""], ["in  comparison  with  nonadjuvanted  SD-IIVs,  particularly  in", "Randomized Studies Comparing HD-IIV, RIV, and aIIV"], ["prevention of influenza-associated hospitalizations. The size of", "with  Nonadjuvanted  SD-IIVs:  Prevention  of  Influenza-"], ["this relative benefit has varied from season to season and is not", "Associated Hospitalizations and Other Serious Events. No"], ["seen in all studies in all seasons, making it difficult to generalize", "data are available from randomized trials evaluating prevention"], ["the findings to all or most seasons. Studies directly comparing", "of laboratory-confirmed influenza-associated hospitalizations"], ["HD-IIV, RIV, and aIIV with one another are few and do not", "as a primary outcome. In a secondary analysis from a two-"], ["support a conclusion that any one of these vaccines is consistently", "season  randomized  trial  of  HD-IIV3  versus  nonadjuvanted"], ["superior to the others across seasons (70\u201372,79\u201381).", "SD-IIV3  assessing  serious  adverse  events  (SAEs)  (including"], ["Of note, for the 2020\u201321 season, quadrivalent formulations", "hospitalizations)  associated  with  laboratory  confirmation  of"], ["of  high-dose  (HD-IIV4)  and  adjuvanted  (aIIV4)  influenza", "influenza performed outside of the study (82) and a post hoc"], ["vaccines  were  introduced.  Trivalent  formulations  of", "analysis of pneumonia- and influenza-related hospitalizations"], ["these  vaccines  are  no  longer  available.  Data  summarizing", "from a randomized study of HD-IIV3 versus nonadjuvanted"], ["comparisons of these newer quadrivalent formulations relative", "SD-IIV4  (83),  there  was  no  difference  in  risk  for  these"], ["to  nonadjuvanted  SD-IIV4s  against  laboratory-confirmed", "events between the two groups (certainty level: 2, moderate)."], ["influenza outcomes are not yet available.", "However,  additional  data  are  available  from  two  single-"], ["Literature concerning the efficacy, effectiveness, and safety of", "season,  cluster-randomized  studies  conducted  among  U.S."], ["HD-IIV, RIV, and aIIV versus nonadjuvanted SD-IIVs and of each", "nursing homes (in which nursing homes were randomized to"], ["of these three vaccines with one another was reviewed, focusing", "vaccine groups rather than individual persons) that examined"], ["on published studies performed during nonpandemic influenza", "prevention  of  pneumonia  and  influenza  diagnostic\u2013coded"], ["seasons. A description of the systematic review and GRADE is", "hospitalizations. One such study noted a benefit of HD-IIV3"], ["available at https://www.cdc.gov/vaccines/acip/recs/grade/influenza-", "relative  to  nonadjuvanted  SD-IIV3  (adjusted  relative  risk:"], ["older-adults.html. An abbreviated summary follows.", "0.79; 95% CI: 0.66\u20130.95; certainty level: 2, moderate) (84)."], ["12 \nMMWR  /  August 26, 2022  /  Vol. 71  /  No. 1", "US Department of Health and Human Services/Centers for Disease Control and Prevention"]]}
{"id": "5714383e-212c-465a-889d-07f496b6cd4c", "page": 15, "type": "table", "data": [["Recommendations and Reports", ""], ["The second noted a benefit of aIIV3 relative to nonadjuvanted", "vaccine (68). One postlicensure randomized clinical trial in the"], ["SD-IIV3  (adjusted  hazard  ratio:  0.79;  95%  CI:  0.65\u20130.96;", "United States evaluated the comparative safety of aIIV3 compared"], ["certainty level: 2, moderate) (85).", "with HD-IIV3 in 757 adults aged \u226565 years (88). For the primary"], ["", "outcome, the proportion of participants who reported moderate"], ["Observational Studies Comparing HD-IIV, RIV, and aIIV", "to  severe  injection  site  pain  that  limited  or  prevented  activity"], ["with  Nonadjuvanted  SD-IIVs:  Prevention  of  Influenza-", "after aIIV3 (12 participants [3.2%]) was noninferior compared"], ["Associated Hospitalizations and Deaths. Observational studies", "with  the  proportion  reporting  this  outcome  after  vaccination"], ["comparing  HD-IIV  and  aIIV  with  nonadjuvanted  SD-IIVs", "with HD-IIV3 (22 participants [5.8%]). No participant sought"], ["are  more  numerous  than  randomized  studies  and  cover  more", "medical care for a solicited reaction symptom, and none had a"], ["influenza  seasons.  Many  of  these  studies  assessed  diagnostic", "SAE determined by study investigators to be related to vaccine"], ["code\u2013defined (rather than laboratory-confirmed) outcomes. In", "within 43 days after vaccination."], ["these studies, an overall modest relative benefit in prevention of", ""], ["", "Immunocompromised Persons"], ["diagnostic  code\u2013defined  influenza-associated  hospitalizations", ""], ["has  been  observed  for  HD-IIV3  (70\u201377)  and  aIIV3  (70\u201372)", "ACIP  recommends  that  persons  with  compromised"], ["versus nonadjuvanted SD-IIV3s. Relative benefit was not found", "immunity  (including  but  not  limited  to  persons  with"], ["in every study for all evaluated seasons for either HD-IIV3 or", "congenital  and  acquired  immunodeficiency  states,  persons"], ["aIIV3. Published observational studies of RIV are fewer than for", "who  are  immunocompromised  due  to  medications,  and"], ["HD-IIV and aIIV. A retrospective analysis of relative effectiveness", "persons with anatomic and functional asplenia) should receive"], ["of RIV4 versus SD-IIV4 against influenza-coded hospitalizations", "an  age-appropriate  IIV4  or  RIV4.  ACIP  recommends  that"], ["among Medicare beneficiaries during the 2019\u201320 season noted a", "LAIV4 not be used for these groups because of the uncertain"], ["relative effectiveness of 17% (95% CI: 9%\u201324%; certainty level:", "but biologically plausible risk for disease attributable to the"], ["3, low) (72). Observational studies that address relative benefit", "live vaccine virus. Use of LAIV4 in persons with these and"], ["in protection against influenza-associated deaths are limited. Two", "other  conditions  is  discussed  in  more  detail  (see  Dosage,"], ["retrospective cohort studies including three influenza seasons noted", "Administration, Contraindications, and Precautions) (Table 2)."], ["a  relative  benefit  of  HD-IIV3  compared  with  nonadjuvanted", "Immunocompromised  states  comprise  a  heterogeneous"], ["SD-IIV3  (69,78)  diagnostic  code\u2013defined  deaths  (pooled  rate", "range of conditions with varying risks for severe infections."], ["ratio: 0.69; 95% CI: 0.57\u20130.84; certainty level: 3, low).", "In  many  instances,  limited  data  are  available  regarding  the"], ["Observational  Studies  Comparing  Effectiveness  of", "effectiveness  of  influenza  vaccines  in  the  setting  of  specific"], ["HD-IIV, RIV, and aIIV with One Another. Data reflecting", "immunocompromised  states  (89). Timing  of  vaccination"], ["comparisons  of  HD-IIV,  aIIV,  and  RIV  with  one  another", "might  be  a  consideration  (e.g.,  vaccinating  during  a  period"], ["are  more  limited  than  comparisons  with  nonadjuvanted", "either before or after an immunocompromising intervention)."], ["SD-IIVs.  Observational  studies  have  compared  HD-IIV3", "The  Infectious  Diseases  Society  of  America  has  published"], ["versus  aIIV3  (70\u201372,79\u201381),  HD-IIV3  versus  RIV4  (72),", "detailed guidance for the selection and timing of vaccines for"], ["and aIIV3 versus RIV4 (72). A retrospective cohort analysis", "persons with specific immunocompromising conditions (90)."], ["noted relative effectiveness of RIV4 compared with HD-IIV3", "Immune response to influenza vaccines might be blunted in"], ["(relative effectiveness: 11%; 95% CI: 3%\u201318%; certainty level:", "persons with certain conditions, such as congenital immune"], ["3, low) and with aIIV3 (relative effectiveness: 11%; 95% CI:", "deficiencies, and in persons receiving cancer chemotherapy or"], ["3%\u201317%;  certainty  level:  3,  low);  these  data  covered  only", "immunosuppressive medications."], ["a single influenza season. Data do not point to a consistent", ""], ["", "Persons with a History of Guillain-Barr\u00e9 Syndrome"], ["relative benefit of one of these three influenza vaccines over", ""], ["", "After Influenza Vaccination"], ["another across multiple seasons.", ""], ["Safety.  In  comparative  safety  studies,  certain  injection  site", "A history of Guillain-Barr\u00e9 syndrome (GBS) within 6 weeks"], ["and systemic reactions were observed more frequently in older", "of a previous dose of any type of influenza vaccine is considered"], ["persons  vaccinated  with  HD-IIV3  and  aIIV3  compared  with", "a  precaution  for  influenza  vaccination  (Table  2).  Persons"], ["nonadjuvanted SD-IIV3 (86,87). In a randomized trial of RIV4", "who are not at higher risk for severe influenza complications"], ["versus nonadjuvanted SD-IIV4 among persons aged \u226550 years,", "(see Populations at Higher Risk for Medical Complications"], ["frequencies of solicited injection site events were similar or lower", "Attributable to Severe Influenza) and who are known to have"], ["among RIV4 recipients; frequency of fever was similar between", "experienced  GBS  within  6  weeks  of  a  previous  influenza"], ["the  two  vaccines.  Frequencies  of  SAEs  were  similar  between", "vaccination typically should not be vaccinated. As an alternative"], ["the two groups, and none was judged to be related to a study", "to  vaccination,  providers  might  consider  using  influenza"]]}
{"id": "172c6724-9bd9-4bae-85f6-781a564d515c", "page": 16, "type": "table", "data": [["Recommendations and Reports", ""], ["antiviral chemoprophylaxis for these persons (91). However,", "ccIIV4 and RIV4, a history of a severe allergic reaction to any"], ["the  benefits  of  influenza  vaccination  might  outweigh  the", "vaccine component is listed as a contraindication; no labeled"], ["possible risks for certain persons who have a history of GBS", "contraindication is specified for a history of allergic reaction to"], ["within 6 weeks after receipt of influenza vaccine and who also", "any other influenza vaccine. However, severe allergic reactions,"], ["are at higher risk for severe complications from influenza.", "although  rare,  can  occur  after  influenza  vaccination,  even"], ["", "among persons with no previous reactions or known allergies."], ["Persons with a History of Egg Allergy", ""], ["", "Although vaccine components can be found in package inserts,"], ["Most  available  influenza  vaccines,  with  the  exceptions", "identifying the causative component without further evaluation"], ["of  RIV4  (Flublok  Quadrivalent,  licensed  for  those  aged", "(i.e., through evaluation and testing for specific allergies) can"], ["\u226518 years) and ccIIV4 (Flucelvax Quadrivalent, licensed for", "be  difficult.  Severe  allergic  reactions  after  vaccination  with"], ["those aged \u22656 months), are prepared by propagation of virus", "an RIV have been reported to VAERS, some of which have"], ["in embryonated eggs and might contain trace amounts of egg", "occurred among persons reporting previous allergic reactions"], ["proteins, such as ovalbumin. For persons who report a history", "to egg or to influenza vaccines and which might represent a"], ["of egg allergy, ACIP recommends the following:", "predisposition  to  development  of  allergic  manifestations  in"], ["\u2022  Persons with a history of egg allergy who have experienced only", "affected persons (92\u201394). Because these rare but severe allergic"], ["urticaria (hives) after exposure to egg should receive influenza", "reactions  can  occur,  ACIP  recommends  the  following  for"], ["vaccine. Any licensed, recommended influenza vaccine (i.e.,", "persons with a history of severe allergic reaction to a previous"], ["any IIV4, RIV4, or LAIV4) that is otherwise appropriate for", "dose of an influenza vaccine (Table 3):"], ["the recipient\u2019s age and health status can be used.", "\u2022  For egg-based IIV4s and LAIV4:"], ["\u2022  Persons who report having had reactions to egg involving", "\u0171"], ["", "A history of severe allergic reaction (e.g., anaphylaxis)"], ["symptoms  other  than  urticaria  (e.g.,  angioedema  or", "to any influenza vaccine (i.e., any egg-based IIV, ccIIV,"], ["swelling, respiratory distress, lightheadedness, or recurrent", "RIV, or LAIV of any valency) is a contraindication to"], ["vomiting)  or  who  required  epinephrine  or  another", "future receipt of all egg-based IIV4s and LAIV4. Each"], ["emergency medical intervention can similarly receive any", "individual  egg-based  IIV4  and  LAIV4  is  also"], ["licensed, recommended influenza vaccine (i.e., any IIV4,", "contraindicated  for  persons  who  have  had  a  severe"], ["RIV4, or LAIV4) that is otherwise appropriate for their", "allergic reaction (e.g., anaphylaxis) to any component"], ["age and health status. If a vaccine other than ccIIV4 or", "of  that  vaccine  (excluding  egg)  (see  Persons  with  a"], ["RIV4 is used, the selected vaccine should be administered", "History of Egg Allergy)."], ["in an inpatient or outpatient medical setting, including", "\u2022  For ccIIV4:"], ["but  not  necessarily  limited  to  hospitals,  clinics,  health", "\u0171 A history of a severe allergic reaction (e.g., anaphylaxis)"], ["departments, and physician offices. Vaccine administration", "to any egg-based IIV, RIV, or LAIV of any valency is a"], ["should be supervised by a health care provider who is able", "precaution for the use of ccIIV4. If ccIIV4 is administered"], ["to recognize and manage severe allergic reactions.", "in  such  instances,  vaccination  should  occur  in  an"], ["All  vaccination  providers  should  be  familiar  with  their", "inpatient or outpatient medical setting and should be"], ["office  emergency  plan  and  be  certified  in  cardiopulmonary", "supervised  by  a  health  care  provider  who  is  able  to"], ["resuscitation (42). No postvaccination observation period is", "recognize and manage severe allergic reactions. Providers"], ["recommended specifically for egg-allergic persons. However,", "also can consider consultation with an allergist to help"], ["ACIP  recommends  that  vaccination  providers  consider", "determine the vaccine component responsible for the"], ["observing  patients  (seated  or  supine)  for  15  minutes  after", "allergic reaction."], ["administration of any vaccine to decrease the risk for injury", "\u0171 A history of a severe allergic reaction (e.g., anaphylaxis)"], ["should syncope occur (42).", "to any ccIIV of any valency or to any component of"], ["", "ccIIV4 is a contraindication to future receipt of ccIIV4."], ["Persons with Previous Allergic Reactions to", ""], ["", "\u2022  For RIV4:"], ["Influenza Vaccines", ""], ["", "\u0171 A history of a severe allergic reaction (e.g., anaphylaxis)"], ["As  is  the  case  for  all  vaccines,  influenza  vaccines  contain", "to any egg-based IIV, ccIIV, or LAIV of any valency is"], ["various components that might cause allergic and anaphylactic", "a precaution for the use of RIV4. If RIV4 is administered"], ["reactions. Most influenza vaccine package inserts list among", "in  such  instances,  vaccination  should  occur  in  an"], ["contraindications  to  their  use  a  history  of  previous  severe", "inpatient or outpatient medical setting and should be"], ["allergic reaction (e.g., anaphylaxis) to any component of the", "supervised  by  a  health  care  provider  who  is  able  to"], ["vaccine  or  to  a  previous  dose  of  any  influenza  vaccine.  For", "recognize and manage severe allergic reactions. Providers"]]}
{"id": "a651039a-71fd-444d-b234-d7f19425943c", "page": 17, "type": "table", "data": [["Recommendations and Reports", ""], ["can also consider consultation with an allergist to help", "Use of Influenza Antiviral Medications"], ["determine the vaccine component responsible for the", ""], ["", "Administration of IIV4 or RIV4 to persons receiving influenza"], ["allergic reaction.", ""], ["", "antiviral  medications  for  treatment  or  chemoprophylaxis  of"], ["\u0171 A history of a severe allergic reaction (e.g., anaphylaxis)", ""], ["", "influenza is acceptable. Data concerning vaccination with LAIV4"], ["to any RIV of any valency or to any component of RIV4", ""], ["", "in the setting of influenza antiviral use are not available. However,"], ["is a contraindication to future receipt of RIV4.", ""], ["", "influenza antiviral medications might interfere with the action"], ["", "of LAIV4 because this vaccine contains live influenza viruses."], ["Vaccination Issues for Travelers", ""], ["", "The  package  insert  for  LAIV4  notes  that  antiviral  agents"], ["In temperate climate regions of the Northern and Southern", ""], ["", "might  reduce  the  effectiveness  of  the  vaccine  if  given  within"], ["Hemispheres, influenza activity is seasonal, occurring during", ""], ["", "the interval from 48 hours before to 14 days after vaccination"], ["approximately October\u2013May in the Northern Hemisphere and", ""], ["", "(99).  However,  the  newer  influenza  antivirals  peramivir  and"], ["April\u2013September in the Southern Hemisphere. In the tropics,", ""], ["", "baloxavir have longer half-lives than oseltamivir and zanamivir,"], ["influenza might occur throughout the year. Travelers can be", ""], ["", "approximately 20 hours for peramivir (100) and 79 hours for"], ["exposed to influenza when traveling to an area where influenza", ""], ["", "baloxavir  (101),  and  could  interfere  with  the  replication  of"], ["is circulating or when traveling as part of large tourist groups", ""], ["", "LAIV4 if administered >48 hours before vaccination. Potential"], ["(e.g., on cruise ships) that include persons from areas of the", ""], ["", "interactions between influenza antivirals and LAIV4 have not"], ["world where influenza viruses are circulating (95\u201398).", ""], ["", "been studied, and the ideal intervals between administration of"], ["Travelers who want to reduce their risk for influenza should", ""], ["", "these medications and LAIV4 are not known. Assuming a period"], ["consider  influenza  vaccination,  preferably  at  least  2  weeks", ""], ["", "of at least 5 half-lives for substantial decrease in drug levels (102),"], ["before departure. In particular, persons who live in the United", ""], ["", "a reasonable assumption is that that peramivir might interfere"], ["States and are at higher risk for influenza complications and", ""], ["", "with  the  mechanism  of  LAIV4  if  administered  from  5  days"], ["who were not vaccinated with influenza vaccine during the", ""], ["", "before through 2 weeks after vaccination and baloxavir might"], ["previous Northern Hemisphere fall or winter should consider", ""], ["", "interfere if administered from 17 days before through 2 weeks"], ["receiving influenza vaccination before departure if they plan", ""], ["", "after vaccination. The interval between influenza antiviral receipt"], ["to travel to the tropics, to the Southern Hemisphere during", ""], ["", "and LAIV4 during which interference might occur could be"], ["the Southern Hemisphere influenza season (April\u2013September),", ""], ["", "further prolonged in the presence of medical conditions that"], ["or  with  organized  tourist  groups  or  on  cruise  ships  to  any", ""], ["", "delay medication clearance (e.g., renal insufficiency). Persons"], ["location.  Persons  at  higher  risk  who  received  the  previous", ""], ["", "who receive these medications during these periods before or"], ["season\u2019s  influenza  vaccine  before  travel  should  consult  with", ""], ["", "after  receipt  of  LAIV4  should  be  revaccinated  with  another"], ["their  health  care  provider  to  discuss  the  risk  for  influenza", ""], ["", "appropriate influenza vaccine (e.g., IIV4 or RIV4)."], ["and other travel-related diseases before embarking on travel", ""], ["during the summer. All persons (regardless of risk status) who", "Administration of Influenza Vaccines with"], ["are vaccinated in preparation for travel before the upcoming", "Other Vaccines"], ["influenza season\u2019s vaccine is available should receive the current", ""], ["", "IIV4s  and  RIV4  may  be  administered  simultaneously  or"], ["vaccine the following fall or winter.", ""], ["", "sequentially with other inactivated vaccines or live vaccines."], ["Influenza vaccine formulated for the Southern Hemisphere", ""], ["", "Injectable  vaccines  that  are  given  concomitantly  should"], ["might  differ  in  viral  composition  from  the  Northern", ""], ["", "be  administered  at  separate  anatomic  sites.  LAIV4  can  be"], ["Hemisphere  vaccine.  For  persons  traveling  to  the  Southern", ""], ["", "administered  simultaneously  with  other  live  or  inactivated"], ["Hemisphere  during  the  Southern  Hemisphere  influenza", ""], ["", "vaccines.  However,  if  two  live  vaccines  are  not  given"], ["season, receipt of a current U.S.-licensed Southern Hemisphere", ""], ["", "simultaneously, at least 4 weeks should pass after administration"], ["influenza  vaccine  formulation  before  departure  might  be", ""], ["", "of one live vaccine (such as LAIV4) before another live vaccine"], ["reasonable but might not be feasible because of limited access to", ""], ["", "is administered (42)."], ["or unavailability of Southern Hemisphere formulations in the", ""], ["", "Current guidance concerning administration of current U.S.-"], ["United States. Most Southern Hemisphere influenza vaccine", ""], ["", "approved or -authorized COVID-19 vaccines indicates that"], ["formulations are not licensed in the United States, and they", ""], ["", "these vaccines may be given with influenza vaccines (https://"], ["are typically not commercially available. More information on", ""], ["", "www.cdc.gov/vaccines/covid-19/clinical-considerations/"], ["influenza vaccines and travel is available at https://wwwnc.cdc.", ""], ["", "interim-considerations-us.html). Providers should be aware of"], ["gov/travel/diseases/influenza-seasonal-zoonotic-and-pandemic.", ""], ["", "the potential for increased reactogenicity with coadministration"], ["", "and  should  consult  updated  CDC  guidance  as  more"]]}
{"id": "65f7d70d-663e-490a-aa4d-c7ddc6fc1782", "page": 18, "type": "table", "data": [["Recommendations and Reports", ""], ["information becomes available. If administered simultaneously,", "and PCV13 did not reduce fever prevalence after vaccination"], ["COVID-19  vaccines  and  influenza  vaccines  that  might  be", "(113). Increased risk for febrile seizures in this age group has"], ["more  likely  to  cause  an  injection  site  reaction  (e.g.,  aIIV4", "been  noted  within  days  0\u20131  after  coadministration  of  IIV"], ["or  HD-IIV4)  should  be  administered  in  different  limbs,  if", "with PCV7, PCV13, or DTaP vaccines during the 2006\u201307"], ["possible.  In  an  interim  analysis  of  a  study  of  concomitant", "through 2010\u201311 seasons (114) and with PCV13 during the"], ["administration of HD-IIV4 and a booster dose of an mRNA", "2014\u201315 season (115). Although concerning to parents, most"], ["COVID-19 vaccine (administered in separate upper arm sites)", "febrile  seizures  are  brief  and  have  a  good  prognosis  (116)."], ["compared with administration of either vaccine alone among", "After  considering  the  risks  and  benefits,  no  changes  in  the"], ["296 persons aged \u226565 years, overall reactogenicity up to 7 days", "recommendations for administration of these vaccines were"], ["postvaccination  was  similar  between  the  coadministration", "made.  Surveillance  of  febrile  seizures  is  ongoing  through"], ["group  and  the  group  that  received  the  mRNA  COVID-19", "VAERS,  and  the  VSD  annual  influenza  safety  surveillance"], ["vaccine  alone;  reactogenicity  rates  in  the  group  receiving", "includes monitoring for seizures after vaccinations. Studies of"], ["HD-IIV4 alone were lower. No SAEs were observed. Immune", "concomitant administration of LAIV with other vaccines are"], ["response  was  similar  between  the  mRNA  COVID-19  and", "limited. Concurrent administration of LAIV3 with measles,"], ["coadministration groups (103).", "mumps, and rubella (MMR) and varicella vaccine to children"], ["Relatively  limited  data  are  available  on  the  concomitant", "was  not  associated  with  diminished  immunogenicity  of"], ["administration  of  influenza  vaccines  with  other  vaccines.", "antigens in any of the vaccines in one study (117); diminished"], ["Studies  of  live  attenuated  zoster  vaccine  and  IIV3  (104)  or", "response to rubella was observed in another study examining"], ["IIV4  (105)  among  persons  aged  \u226550  years  noted  similar", "coadministration  of  LAIV3  and  MMR  (118).  No  safety"], ["antibody responses whether the two vaccines were administered", "concerns were noted in these studies."], ["concomitantly or 4 weeks apart. In certain studies, reduced", "In  recent  years,  several  vaccines  containing  nonaluminum"], ["responses  have  been  noted  to  13-valent  pneumococcal", "adjuvants  have  been  licensed  for  use  in  the  United  States  for"], ["conjugate vaccine (PCV13) (106,107), tetanus antigens (108),", "the  prevention  of  various  infectious  diseases. These  include"], ["and pertussis antigens (108) when coadministered with IIV3", "AS01B (in Shingrix, recombinant zoster subunit vaccine) (119),"], ["to adults; in most instances, the clinical significance of this is", "MF59  (in  Fluad  Quadrivalent  [aIIV4])  (120),  and  cytosine"], ["uncertain. Simultaneous administration of IIV4 and 23-valent", "phosphoguanine  oligodeoxynucleotide  (in  Heplisav-B,  a"], ["pneumococcal  polysaccharide  vaccine  (PPSV23)  to  persons", "recombinant hepatitis B surface antigen vaccine) (121). Data are"], ["aged \u226565 years was associated with lower seroprotection rates", "limited regarding coadministration of these vaccines with other"], ["to  one  influenza  B  antigen  at  4\u20136  weeks  postvaccination", "adjuvanted  or  nonadjuvanted  vaccines,  including  COVID-19"], ["compared  with  sequential  administration  2  weeks  apart.", "vaccines. Coadministration of Shingrix with nonadjuvanted IIV4"], ["Seroprotection  was  not  significantly  different  between  the", "has been studied, and no evidence of decreased immunogenicity or"], ["two groups for any of the four influenza antigens at 6 months", "safety concerns was noted (122). The immunogenicity and safety"], ["postvaccination  (109).  Reassuring  safety  profiles  have  been", "of simultaneous or sequential administration of two nonaluminum"], ["noted  for  simultaneous  administration  of  IIVs  with  live", "adjuvant\u2013containing vaccines have not been evaluated, and the"], ["attenuated  zoster  vaccine  (104,105);  PCV13  (106,107);", "ideal  interval  between  such  vaccines  when  given  sequentially"], ["PPSV23 (109,110); tetanus toxoid, reduced diphtheria toxoid,", "is not known. In the study of Shingrix and IIV4 (122), most"], ["and acellular pertussis (Tdap) vaccine among adults (108); and", "reactogenicity  symptoms  resolved  within  4  days.  Because  of"], ["Tdap in pregnancy (111). Although increased prevalence of", "the  limited  data  on  the  safety  of  simultaneous  administration"], ["injection site or systemic adverse reactions has been noted with", "of  two  or  more  vaccines  containing  nonaluminum  adjuvants"], ["concurrent administration in certain studies, these symptoms", "and the availability of nonadjuvanted influenza vaccine options,"], ["have usually been reported to be mild or moderate.", "selection of a nonadjuvanted influenza vaccine may be considered"], ["Among children aged 6 through 23 months, coadministration", "in  situations  in  which  influenza  vaccine  and  another  vaccine"], ["of  IIV3  and  PCV13  was  associated  with  increased  risk", "containing  a  nonaluminum  adjuvant  are  to  be  administered"], ["for  fever  on  the  day  of  vaccination  and  the  day  after  (i.e.,", "concomitantly.  However,  influenza  vaccination  should  not  be"], ["days 0\u20131 postvaccination) in an observational study conducted", "delayed if a specific vaccine is not available. As recommended for"], ["during  the  2011\u201312  season  (112).  A  randomized  clinical", "all  vaccines,  vaccines  with  nonaluminum  adjuvants  should  be"], ["trial  during  the  2017\u201318  influenza  season  suggested  that", "administered at separate anatomic sites from other vaccines that"], ["delaying IIV4 administration by 2 weeks in children receiving", "are given concomitantly (42)."], ["diphtheria and tetanus toxoids and acellular pertussis (DTaP)", ""]]}
{"id": "b35b82cf-2c05-4baf-a8fc-0ad61ece04a1", "page": 19, "type": "table", "data": [["Recommendations and Reports", ""], ["", "for the different types of influenza vaccines are summarized"], ["Influenza Vaccine Composition and", ""], ["", "(Tables 2 and 3), as are dose volumes (Table 4)."], ["Available Vaccines", ""], ["", "Not  all  influenza  vaccines  are  likely  to  be  uniformly"], ["", "available in any specific practice setting or geographic locality."], ["Influenza Vaccine Composition for the", ""], ["", "Vaccination should not be delayed to obtain a specific product"], ["2022\u201323 Season", ""], ["", "when an appropriate one is available. Within these guidelines"], ["All  influenza  vaccines  licensed  in  the  United  States  will", "and  approved  indications,  ACIP  makes  no  preferential"], ["contain components derived from influenza viruses antigenically", "recommendation  for  the  use  of  any  one  influenza  vaccine"], ["similar to those recommended by FDA (https://www.fda.gov/", "over  another  when  more  than  one  licensed,  recommended,"], ["advisory-committees/advisory-committee-calendar/vaccines-", "and age-appropriate vaccine is available, with the exception"], ["and-related-biological-products-advisory-committee-march-3-", "of selection of influenza vaccines for persons aged \u226565 years"], ["2022-meeting-announcement). All influenza vaccines expected", "(see Older Adults)."], ["to be available in the United States for the 2022\u201323 season will be", "Since  the  publication  of  the  previous  season\u2019s"], ["quadrivalent vaccines. For the 2022\u201323 season, U.S. egg-based", "recommendations, FDA has approved a labeling change for"], ["influenza vaccines (i.e., vaccines other than ccIIV4 and RIV4)", "Flucelvax Quadrivalent (see Recent Influenza Vaccine Labeling"], ["will contain HA derived from", "Changes).  Additional  new  licensures  and  changes  to  FDA-"], ["\u2022  an influenza A/Victoria/2570/2019 (H1N1)pdm09-like", "approved labeling might occur after publication of this report."], ["virus,", "As these changes occur and new vaccines become available,"], ["\u2022  an influenza A/Darwin/9/2021 (H3N2)-like virus,", "they will be reflected in the online version of Table 1, available"], ["\u2022  an influenza B/Austria/1359417/2021 (Victoria lineage)-", "at  https://www.cdc.gov/flu/professionals/acip/2022-2023/"], ["like virus, and", "acip-table.htm."], ["\u2022  an influenza B/Phuket/3073/2013 (Yamagata lineage)-like", ""]]}
{"id": "e653e4e7-2402-491d-b02a-a92ac46539a6", "page": 20, "type": "table", "data": [["Recommendations and Reports", ""], ["propagated  in  eggs.  For  Flucelvax  Quadrivalent,  reference", "aged \u226536 months, the remaining volume needed to make a full"], ["vaccine viruses are propagated in Madin-Darby canine kidney", "dose should be administered during the same vaccination visit"], ["cells instead of eggs (125).", "or, if measuring the needed remaining volume is a challenge,"], ["Two additional IIV4s that will be available for the 2022\u201323", "administering a repeat dose at the full volume is acceptable."], ["season are approved for persons aged \u226565 years. These vaccines", "If the error is discovered later (after the recipient has left the"], ["are egg based. Quadrivalent high-dose inactivated influenza", "vaccination setting), a full dose should be administered as soon"], ["vaccine (Fluzone High-Dose Quadrivalent; HD-IIV4) contains", "as the recipient can return. Vaccination with a formulation"], ["60 \u00b5g of HA per vaccine virus (240 \u00b5g total) in a 0.7-mL dose", "approved for adult use should be counted as a single dose if"], ["(126). Quadrivalent adjuvanted inactivated influenza vaccine", "inadvertently administered to a child."], ["(Fluad Quadrivalent; aIIV4) contains 15 \u00b5g of HA per vaccine", "IIV4s are administered intramuscularly (IM). For adults and"], ["virus (60 \u00b5g total) and MF59 adjuvant (120).", "older children, the deltoid muscle is the preferred site. Infants"], ["Dosage and Administration. Standard-dose nonadjuvanted", "and younger children should be vaccinated in the anterolateral"], ["IIV4s are approved for children aged as young as 6 months.", "thigh. Additional specific guidance regarding site selection and"], ["Certain of these IIV4s are approved at different dose volumes", "needle length for IM injection is provided in the ACIP General"], ["for very young children than for older children and adults. Care", "Best Practice Guidelines for Immunization (42)."], ["should be taken to administer an age-appropriate vaccine at", "One IIV4, Afluria Quadrivalent, is licensed for IM injection"], ["the approved dose volume for each needed dose (see Children", "via  the  PharmaJet  Stratis  jet  injector  for  persons  aged  18"], ["Aged 6 Through 35 Months: Influenza Vaccine Dose Volumes)", "through 64 years (43). Persons in this age group may receive"], ["(Tables 1 and 4):", "Afluria  Quadrivalent  via  either  needle  and  syringe  or  this"], ["\u2022  Afluria  Quadrivalent: The  approved  dose  volume  for", "specific jet injection device. Children aged 6 months through"], ["children aged 6 through 35 months is 0.25 mL per dose.", "17 years and adults aged \u226565 years should receive this vaccine"], ["Persons aged \u226536 months (\u22653 years) should receive 0.5 mL", "by needle and syringe only. No other IIV4s are licensed for"], ["per dose.", "administration by jet injector."], ["\u2022  Fluarix Quadrivalent: The approved dose volume is 0.5 mL", "Contraindications  and  Precautions  for  the  Use  of"], ["per dose for all persons aged \u22656 months.", "IIV4s.  Manufacturer  package  inserts  and  updated  CDC"], ["\u2022  Flucelvax  Quadrivalent: The  approved  dose  volume  is", "and ACIP guidance should be consulted for information on"], ["0.5 mL per dose for all persons aged \u22656 months.", "contraindications  and  precautions  for  individual  influenza"], ["\u2022  FluLaval  Quadrivalent: The  approved  dose  volume  is", "vaccines. Each IIV, whether egg-based or cell culture\u2013based,"], ["0.5 mL per dose for all persons aged \u22656 months.", "has a labeled contraindication for persons with a history of"], ["\u2022  Fluzone  Quadrivalent: The  approved  dose  volume  for", "a  severe  allergic  reaction  to  any  component  of  that  vaccine"], ["children aged 6 through 35 months is either 0.25 mL or", "(Table  2).  Although  egg  is  a  component  of  all  IIV4s  other"], ["0.5  mL  per  dose.  Persons  aged  \u226536  months  (\u22653  years)", "than  ccIIV4,  ACIP  makes  specific  recommendations  for"], ["should receive 0.5 mL per dose.", "the  use  of  influenza  vaccine  for  persons  with  egg  allergy"], ["If prefilled syringes are not available, the appropriate volume", "(see  Persons  with  a  History  of  Egg  Allergy).  All  egg-based"], ["can be administered from a single-dose or multidose vial. If", "IIV4s are contraindicated in persons who have had a severe"], ["a  0.5-mL  single-dose  vial  is  used  for  a  0.25-mL  dose  for  a", "allergic reaction (e.g., anaphylaxis) to a previous dose of any"], ["child aged 6 through 35 months, only half of the vial volume", "influenza vaccine (any egg-based IIV, ccIIV, RIV, or LAIV of"], ["should  be  administered,  and  the  remaining  half  should  be", "any valency). Use of ccIIV4 is contraindicated in persons who"], ["discarded. Of note, dose volume is distinct from the number", "have had a severe allergic reaction (e.g., anaphylaxis) to any"], ["of doses. Children in this age group who require 2 doses for", "ccIIV of any valency. A history of severe allergic reaction (e.g.,"], ["2022\u201323 need 2 separate doses administered \u22654 weeks apart,", "anaphylaxis) to any other influenza vaccine (i.e., any egg-based"], ["regardless of the specific IIV4 used and volume given for each", "IIV, RIV, or LAIV of any valency) is a precaution for the use"], ["dose (see Children Aged 6 Months Through 8 Years: Number", "of  ccIIV4  (see  Persons  with  Previous  Allergic  Reactions  to"], ["of Influenza Vaccine Doses) (Figure).", "Influenza Vaccines) (Tables 2 and 3). If ccIIV4 is administered"], ["For children aged 36 months (3 years) through 17 years and", "in such an instance, vaccination should occur in an inpatient"], ["adults aged \u226518 years, the dose volume for IIV4s is 0.5 mL per", "or outpatient medical setting and should be supervised by a"], ["dose, with the exception of Fluzone High-Dose Quadrivalent", "health care provider who is able to recognize and manage severe"], ["(HD-IIV4,  licensed  for  persons  aged  \u226565  years),  for  which", "allergic reactions. Providers can also consider consultation with"], ["the correct volume is 0.7 mL per dose. If a smaller vaccine", "an allergist to help identify the vaccine component responsible"], ["dose (e.g., 0.25 mL) is inadvertently administered to a person", "for the reaction. Information about vaccine components can"]]}
{"id": "ca7da13a-4ab5-442c-b48a-0963ffd79a98", "page": 21, "type": "table", "data": [["allergic reaction (e.g., anaphylaxis) to a previous dose of any", "is uncertain but biologically plausible potential risk associated"], ["RIV of any valency or any component of RIV4. A history of a", "with live viruses or limited data for use of LAIV."], ["severe allergic reaction (e.g., anaphylaxis) to any other influenza", "Contraindications to use of LAIV4 include the following:"], ["vaccine (i.e., any egg-based IIV, ccIIV, or LAIV of any valency)", "\u2022  Severe allergic reaction (e.g., anaphylaxis) to any component"], ["is a precaution for the use of RIV4. If RIV4 is administered", "of the vaccine or to a previous dose of any influenza vaccine"], ["in such an instance, vaccination should occur in an inpatient", "(i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency;"], ["or outpatient medical setting and should be supervised by a", "a  labeled  contraindication  noted  in  the  package  insert)."], ["health care provider who is able to recognize and manage severe", "However, ACIP makes an exception for allergy to egg (see"], ["allergic reactions. Providers can also consider consulting with", "Persons with a History of Egg Allergy)."], ["an allergist to help identify the vaccine component responsible", "\u2022  Children and adolescents receiving concomitant aspirin- or"], ["for  the  reaction.  Moderate  or  severe  acute  illness  with  or", "salicylate-containing medications, because of the potential"], ["without fever is a general precaution for vaccination (42). A", "risk for Reye syndrome (a labeled contraindication noted"], ["history of GBS within 6 weeks after receipt of a previous dose", "in the package insert)."], ["of influenza vaccine is considered a precaution for the use of all", "\u2022  Children  aged  2  through  4  years  who  have  received  a"], ["influenza vaccines (Table 2). RIV4 is not licensed for children", "diagnosis of asthma or whose parents or caregivers report"], ["aged <18 years.", "that  a  health  care  provider  has  told  them  during  the"], ["", "preceding  12  months  that  their  child  had  wheezing  or"], ["Quadrivalent Live Attenuated Influenza", ""], ["", "asthma  or  whose  medical  record  indicates  a  wheezing"], ["Vaccine (LAIV4)", ""], ["", "episode has occurred during the preceding 12 months."], ["Available Vaccine. One live attenuated influenza vaccine,", "\u2022  Children and adults who are immunocompromised due to"], ["FluMist  Quadrivalent  (LAIV4),  is  expected  to  be  available", "any cause, including but not limited to immunosuppression"], ["during  the  2022\u201323  influenza  season.  LAIV4  is  approved", "caused  by  medications,  congenital  or  acquired"], ["for  persons  aged  2  through  49  years.  LAIV4  contains  live", ""]]}
{"id": "9dddc002-3f82-4796-9ce5-3126a721a7db", "page": 21, "type": "table", "data": [["Recommendations and Reports", ""], ["be found in the package inserts for each vaccine. Prophylactic", "restricted at higher temperatures, 39\u00b0C for influenza A viruses"], ["use  of  antiviral  agents  is  an  option  that  can  be  considered", "and 37\u00b0C for influenza B viruses). These viruses replicate in"], ["for preventing influenza among persons who cannot receive", "the nasopharynx, which is necessary to promote an immune"], ["vaccine, particularly for those who are at higher risk for medical", "response (99). No preference is expressed for LAIV4 versus"], ["complications attributable to severe influenza (91).", "other influenza vaccines used within specified indications."], ["Moderate  or  severe  acute  illness  with  or  without  fever  is", "Dosage  and  Administration.  LAIV4  is  administered"], ["a general precaution for vaccination (42). A history of GBS", "intranasally  using  the  supplied  prefilled,  single-use  sprayer"], ["within 6 weeks after receipt of a previous dose of influenza", "containing 0.2 mL of vaccine. Approximately 0.1 mL (i.e., half"], ["vaccine is considered a precaution for the use of all influenza", "of the total sprayer contents) is sprayed into the first nostril while"], ["vaccines (Table 2).", "the recipient is in the upright position. An attached dose-divider"], ["", "clip is removed from the sprayer to permit administration of the"], ["Quadrivalent Recombinant Influenza Vaccine (RIV4)", ""], ["", "second half of the dose into the other nostril. If the recipient"], ["Available Vaccine.  One  recombinant  influenza  vaccine,", "sneezes  immediately  after  administration,  the  dose  should"], ["Flublok  Quadrivalent  (RIV4),  is  expected  to  be  available", "not be repeated. However, if nasal congestion is present that"], ["during the 2022\u201323 influenza season. RIV4 is approved for", "might  impede  delivery  of  the  vaccine  to  the  nasopharyngeal"], ["persons aged \u226518 years. This vaccine contains recombinant HA", "mucosa, deferral of administration should be considered until"], ["produced in an insect cell line using genetic sequences from", "resolution of the illness, or another appropriate vaccine should"], ["cell-derived influenza viruses and is manufactured without the", "be administered instead. Each total dose of 0.2 mL contains"], ["use of influenza viruses or eggs (127).", "106.5\u20137.5 fluorescent focus units of each vaccine virus (99)."], ["Dosage and Administration: RIV4 is administered by IM", "Contraindications and Precautions for the Use of LAIV4."], ["injection via needle and syringe. A 0.5-mL dose contains 45 \u00b5g", "Conditions considered by ACIP to be contraindications and"], ["of HA derived from each vaccine virus (180 \u00b5g total).", "precautions for the use of LAIV4 are summarized (Table 2)."], ["Contraindications and Precautions for the Use of RIV4.", "These  include  two  labeled  contraindications  that  appear  in"], ["RIV4  is  contraindicated  in  persons  who  have  had  a  severe", "the package insert (99) and other conditions for which there"], ["allergic reaction (e.g., anaphylaxis) to a previous dose of any", "is uncertain but biologically plausible potential risk associated"], ["RIV of any valency or any component of RIV4. A history of a", "with live viruses or limited data for use of LAIV."], ["severe allergic reaction (e.g., anaphylaxis) to any other influenza", "Contraindications to use of LAIV4 include the following:"], ["vaccine (i.e., any egg-based IIV, ccIIV, or LAIV of any valency)", "\u2022  Severe allergic reaction (e.g., anaphylaxis) to any component"], ["is a precaution for the use of RIV4. If RIV4 is administered", "of the vaccine or to a previous dose of any influenza vaccine"], ["in such an instance, vaccination should occur in an inpatient", "(i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency;"], ["or outpatient medical setting and should be supervised by a", "a  labeled  contraindication  noted  in  the  package  insert)."], ["health care provider who is able to recognize and manage severe", "However, ACIP makes an exception for allergy to egg (see"], ["allergic reactions. Providers can also consider consulting with", "Persons with a History of Egg Allergy)."], ["an allergist to help identify the vaccine component responsible", "\u2022  Children and adolescents receiving concomitant aspirin- or"], ["for  the  reaction.  Moderate  or  severe  acute  illness  with  or", "salicylate-containing medications, because of the potential"], ["without fever is a general precaution for vaccination (42). A", "risk for Reye syndrome (a labeled contraindication noted"], ["history of GBS within 6 weeks after receipt of a previous dose", "in the package insert)."], ["of influenza vaccine is considered a precaution for the use of all", "\u2022  Children  aged  2  through  4  years  who  have  received  a"], ["influenza vaccines (Table 2). RIV4 is not licensed for children", "diagnosis of asthma or whose parents or caregivers report"], ["aged <18 years.", "that  a  health  care  provider  has  told  them  during  the"], ["", "preceding  12  months  that  their  child  had  wheezing  or"], ["Quadrivalent Live Attenuated Influenza", ""], ["", "asthma  or  whose  medical  record  indicates  a  wheezing"], ["Vaccine (LAIV4)", ""], ["", "episode has occurred during the preceding 12 months."], ["Available Vaccine. One live attenuated influenza vaccine,", "\u2022  Children and adults who are immunocompromised due to"], ["FluMist  Quadrivalent  (LAIV4),  is  expected  to  be  available", "any cause, including but not limited to immunosuppression"], ["during  the  2022\u201323  influenza  season.  LAIV4  is  approved", "caused  by  medications,  congenital  or  acquired"], ["for  persons  aged  2  through  49  years.  LAIV4  contains  live", ""], ["attenuated influenza viruses that are propagated in eggs. These", ""], ["viruses are cold adapted (so that they replicate efficiently at", ""], ["25\u00b0C) and temperature sensitive (so that their replication is", ""]]}
{"id": "fd76cc91-ecf3-4507-9454-1f6be7b7ab67", "page": 22, "type": "table", "data": [["Recommendations and Reports", ""], ["immunodeficiency states, HIV infection, anatomic asplenia,", "efficacy  trial  conducted  among  4,514  children  aged  \u22652  to"], ["or functional asplenia (such as that due to sickle cell anemia).", "<18 years over three influenza seasons (Southern Hemisphere"], ["\u2022  Close contacts and caregivers of severely immunosuppressed", "2017 and Northern Hemisphere 2017\u201318 and 2018\u201319) (129)."], ["persons who require a protected environment.", "Subsequently,  in  October  2021,  FDA  approved  Flucelvax"], ["\u2022  Pregnancy.", "Quadrivalent for persons aged \u22656 months. Approval was based"], ["\u2022  Persons  with  active  communication  between  the", "on a randomized immunogenicity and safety study conducted"], ["cerebrospinal fluid (CSF) and the oropharynx, nasopharynx,", "among 2,402 children aged 6 through 47 months (of whom 894"], ["nose, or ear or any other cranial CSF leak.", "were aged 6 through 23 months). Children were randomized"], ["\u2022  Persons with cochlear implants, because of the potential for", "in  a  2:1  ratio  to  receive  either  Flucelvax  Quadrivalent"], ["CSF  leak  that  might  exist  for  a  period  after  implantation", "(0.5 mL/dose containing 15 \u00b5g HA per virus for all ages) or a"], ["(providers  might  consider  consultation  with  a  specialist", "licensed comparator egg-based IIV4 (0.25 mL/dose containing"], ["concerning the risk for persistent CSF leak if an age-appropriate", "7.5 \u00b5g HA per virus for those aged 6 through 35 months and"], ["inactivated or recombinant vaccine cannot be used).", "0.5  mL/dose  containing  15  \u00b5g  HA  per  virus  for  those  aged"], ["\u2022  Receipt  of  influenza  antiviral  medication  within  the", "36  through  47  months)  (130).  Flucelvax  Quadrivalent  met"], ["previous 48 hours for oseltamivir and zanamivir, previous", "prespecified immunogenicity criteria for all four viruses. No new"], ["5 days for peramivir, and previous 17 days for baloxavir.", "safety signals were noted, and prevalence of solicited injection"], ["The interval between influenza antiviral receipt and LAIV4", "site and systemic reactions was similar between the two groups."], ["during which interference might potentially occur might", ""], ["be further prolonged in the presence of medical conditions", ""], ["that delay medication clearance (e.g., renal insufficiency).", "Storage and Handling of"], ["Precautions for use of LAIV4 include the following:", ""], ["", "Influenza Vaccines"]]}
{"id": "6d27f196-7f86-4254-b21f-8ff52717942a", "page": 22, "type": "table", "data": [["", "hypertension], renal, hepatic, neurologic, hematologic, or", ""], ["", "", "discarded. Specific recommendations for appropriate refrigerators"], ["", "metabolic disorders [including diabetes mellitus]).", ""], ["", "", "and  temperature  monitoring  equipment  can  be  found  in  the"], ["", "", "Vaccine Storage and Handling Toolkit, available at https://www."], ["", "Recent Influenza Vaccine Labeling Changes", ""], ["", "", "cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html."], ["", "", "Vaccines should not be used beyond the expiration date on"], ["Flucelvax Quadrivalent", "", ""], ["", "", "the label. In addition to the expiration date, multidose vials also"], ["", "Since the publication of the 2021\u201322 ACIP influenza vaccine", ""], ["", "", "might have a beyond-use date (BUD), which specifies the number"], ["", "recommendations, a labeling change for Flucelvax Quadrivalent", ""], ["", "", "of days the vaccine can be kept once first accessed. After being"], ["", "(ccIIV4)  has  occurred.  Flucelvax  Quadrivalent  was  initially", ""], ["", "", "accessed for the first dose, multidose vials should not be used after"], ["", "approved in 2016 for persons aged \u22654 years. Approval for persons", ""], ["", "", "the BUD. If no BUD is provided, then the listed expiration date"], ["", "aged  \u226518  years  was  based  on  a  randomized  immunogenicity", ""], ["", "", "is to be used. Multidose vials should be returned to recommended"], ["", "and safety trial that compared Flucelvax Quadrivalent with the", ""], ["", "", "storage conditions between uses. Package information might also"], ["", "previously approved trivalent formulation of Flucelvax (ccIIV3),", ""], ["", "", "specify a maximum number of doses contained in multidose vials"], ["", "which had previously been licensed for persons aged \u226518 years", ""], ["", "", "(regardless of remaining volume). No more than the specified"], ["", "on the basis of data from a randomized clinical efficacy trial.", ""], ["", "", "number of doses should be removed, and any remainder should"], ["", "Approval for children aged 4 through 17 years also was based on", ""], ["", "", "be discarded. Single-dose vials should not be accessed for more"], ["", "immunogenicity and safety data compared with ccIIV3, with a", ""], ["", "", "than  1  dose.  Providers  should  contact  the  manufacturer  for"], ["", "postmarketing requirement to conduct a clinical efficacy study", ""], ["", "", "information  on  permissible  temperature  excursions  and  other"], ["", "(128). In March 2021, FDA approved Flucelvax Quadrivalent", ""], ["", "", "departures from recommended storage and handling conditions"], ["", "for persons aged \u22652 years on the basis of a randomized clinical", ""], ["", "", "that are not discussed in the package labeling."], ["20", "MMWR  /  August 26, 2022  /  Vol. 71  /  No. 1", "US Department of Health and Human Services/Centers for Disease Control and Prevention"]]}
{"id": "5f4200ba-1c70-414d-91db-e4381e16abeb", "page": 23, "type": "table", "data": [["", "Recommendations and Reports"], ["", "presumption of causation. If the injury or condition is not in the"], ["Additional Sources of Information", ""], ["", "table or does not meet the requirements in the table, persons must"], ["Regarding Influenza and", ""], ["", "prove that the vaccine caused the injury or condition. Claims"], ["Influenza Vaccines", "must be filed with specified time frames. Persons of all ages who"], ["", "receive a VICP-covered vaccine might be eligible to file a claim."], ["Influenza Surveillance, Prevention,", ""], ["", "Additional  information  is  available  at  https://www.hrsa.gov/"], ["and Control", "vaccine-compensation or by calling 1-800-338-2382."]]}
{"id": "c767e7be-ac03-4a48-ae75-2542f6b62810", "page": 23, "type": "table", "data": [["", "receive a VICP-covered vaccine might be eligible to file a claim."], ["Influenza Surveillance, Prevention,", ""], ["", "Additional  information  is  available  at  https://www.hrsa.gov/"], ["and Control", "vaccine-compensation or by calling 1-800-338-2382."], ["Updated  information  regarding  influenza  surveillance,", ""], ["detection,  prevention,  and  control  is  available  at  https://", "Additional Resources"], ["www.cdc.gov/flu. U.S. surveillance data are updated weekly", ""], ["", "ACIP Statements"], ["throughout  the  year  on  FluView  (https://www.cdc.gov/flu/", ""], ["weekly)  and  can  be  viewed  in  FluView  Interactive  (https://", "\u2022  General Best Practice Guidelines for Immunization: Best"], ["www.cdc.gov/flu/weekly/fluviewinteractive.htm). In addition,", "Practices  Guidance  of  the  Advisory  Committee  on"], ["periodic updates regarding influenza are published in MMWR", "Immunization  Practices  (ACIP):  https://www.cdc.gov/"], ["(https://www.cdc.gov/mmwr/index.html).  Additional", "vaccines/hcp/acip-recs/general-recs/index.html"], ["information  regarding  influenza  and  influenza  vaccines  can", "\u2022  Immunization of Health Care Personnel: Recommendations"], ["be  obtained  from  CDCINFO  by  calling  1-800-232-4636.", "of the Advisory Committee on Immunization Practices"], ["State  and  local  health  departments  should  be  consulted", "(ACIP),  2011.  MMWR  Recomm  Rep  2011;60(No."], ["about availability of influenza vaccines, access to vaccination", "RR-7):1\u201345:  https://www.cdc.gov/mmwr/preview/"], ["programs,  information  related  to  state  or  local  influenza", "mmwrhtml/rr6007a1.htm"], ["activity, reporting of influenza outbreaks and influenza-related", "\u2022  Recommended  Adult  Immunization  Schedule  for  Ages"], ["pediatric deaths, and advice concerning outbreak control.", "19 Years  or  Older,  United  States:  https://www.cdc.gov/"], ["", "vaccines/schedules/hcp/imz/adult.html"], ["", "\u2022  Recommended Child and Adolescent Immunization Schedule"], ["Vaccine Adverse Event Reporting System", ""], ["", "for Ages 18 Years or Younger, United States: https://www.cdc."], ["The National Childhood Vaccine Injury Act of 1986 requires", ""], ["", "gov/vaccines/schedules/hcp/imz/child-adolescent.html"], ["health care providers to report any adverse event listed by the", ""]]}
{"id": "b989e95f-f436-42c5-9a15-90318914e538", "page": 24, "type": "table", "data": [["", "Effects of influenza vaccination in the United States during the 2017\u2013"], ["articles/2018/04/influenza-vaccination-during-pregnancy", ""], ["", "2018  influenza  season.  Clin  Infect  Dis  2019;69:1845\u201353."], ["", "PMID:30715278 https://doi.org/10.1093/cid/ciz075"], ["References", ""], ["", "15. CDC. 2020\u201321 flu season summary FAQ. Atlanta, GA: US Department"], ["1. Barker WH. Excess pneumonia and influenza associated hospitalization", "of Health and Human Services, CDC; 2021. https://www.cdc.gov/flu/"], ["during influenza epidemics in the United States, 1970\u201378. Am J Public", "season/faq-flu-season-2020-2021.htm"], ["Health  1986;76:761\u20135.  PMID:3717461  https://doi.org/10.2105/", "16. CDC. Fluview. Weekly influenza surveillance report. Atlanta, GA: US"], ["AJPH.76.7.761", "Department of Health and Human Services, CDC; 2021. https://www."], ["2. Barker  WH,  Mullooly  JP.  Impact  of  epidemic  type  A  influenza  in  a", "cdc.gov/flu/weekly/index.htm"], ["defined  adult  population.  Am  J  Epidemiol  1980;112:798\u2013811.", "17. Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control"], ["PMID:7457471 https://doi.org/10.1093/oxfordjournals.aje.a113052", "of seasonal influenza with vaccines: recommendations of the Advisory"], ["3. Coleman  BL,  Fadel  SA,  Fitzpatrick T, Thomas  SM.  Risk  factors  for", "Committee  on  Immunization  Practices,  United  States,  2021\u201322"], ["serious outcomes associated with influenza illness in high- versus low-", "influenza  season.  MMWR  Recomm  Rep  2021;70(No.  RR-5):1\u201328."], ["and  middle-income  countries:  systematic  literature  review  and  meta-", "PMID:34448800 https://doi.org/10.15585/mmwr.rr7005a1"], ["analysis. Influenza Other Respir Viruses 2018;12:22\u20139. PMID:29197154", "18. Ahmed  F.  ACIP  handbook  for  developing  evidence-based"], ["https://doi.org/10.1111/irv.12504", "recommendations, Version 1.2. Atlanta, GA: US Department of Health"], ["", "and Human Services, CDC; 2013."]]}
{"id": "ba794d4a-ba9b-4dfd-a2c9-e8b1dec976fe", "page": 24, "type": "table", "data": [["Recommendations and Reports", ""], ["", "4. Mullooly JP, Bridges CB, Thompson WW, et al.; Vaccine Safety Datalink"], ["Influenza Vaccine Package Inserts", ""], ["", "Adult Working Group. Influenza- and RSV-associated hospitalizations"], ["\u2022  https://www.fda.gov/vaccines-blood-biologics/vaccines/", "among adults. Vaccine 2007;25:846\u201355. PMID:17074423 https://doi."], ["", "org/10.1016/j.vaccine.2006.09.041"], ["vaccines-licensed-use-united-states", ""], ["", "5. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza"], ["", "in  young  children,  2004\u20132009.  Pediatrics  2013;131:207\u201316."], ["CDC Influenza Antiviral Guidance", ""], ["", "PMID:23296444 https://doi.org/10.1542/peds.2012-1255"], ["\u2022  Influenza Antiviral Medications: Summary for Clinicians:", "6. Poehling  KA,  Edwards  KM,  Weinberg  GA,  et  al.;  New  Vaccine"], ["", "Surveillance  Network. The  underrecognized  burden  of  influenza  in"], ["https://www.cdc.gov/flu/professionals/antivirals/", ""], ["", "young  children.  N  Engl  J  Med  2006;355:31\u201340.  PMID:16822994"], ["summary-clinicians.htm", ""], ["", "https://doi.org/10.1056/NEJMoa054869"], ["", "7. Siston  AM,  Rasmussen  SA,  Honein  MA,  et  al.;  Pandemic  H1N1"], ["Infectious Diseases Society of America Influenza", ""], ["", "Influenza  in  Pregnancy  Working  Group.  Pandemic  2009  influenza"], ["Antiviral Guidance", "A(H1N1) virus illness among pregnant women in the United States."], ["", "JAMA 2010;303:1517\u201325. PMID:20407061 https://doi.org/10.1001/"], ["\u2022  Clinical  Practice  Guidelines  by  the  Infectious  Diseases", "jama.2010.479"], ["Society of America: 2018 Update on Diagnosis, Treatment,", "8. Fragaszy EB, Warren-Gash C, White PJ, et al.; Flu Watch Group. Effects"], ["", "of  seasonal  and  pandemic  influenza  on  health-related  quality  of  life,"], ["Chemoprophylaxis,  and  Institutional  Outbreak", ""], ["", "work and school absence in England: results from the Flu Watch cohort"], ["Management of Seasonal Influenza: https://academic.oup.", ""], ["", "study. Influenza Other Respir Viruses 2018;12:171\u201382. PMID:28991409"], ["com/cid/article/68/6/e1/5251935", "https://doi.org/10.1111/irv.12506"], ["", "9. Van  Wormer  JJ,  King  JP,  Gajewski  A,  McLean  HQ,  Belongia  EA."], ["American Academy of Pediatrics Guidance", "Influenza and workplace productivity loss in working adults. J Occup"], ["", "Environ  Med  2017;59:1135\u20139.  PMID:28759481  https://doi."], ["\u2022  American Academy of Pediatrics Recommendations for", "org/10.1097/JOM.0000000000001120"], ["Prevention  and  Control  of  Influenza  in  Children  (Red", "10. Willis GA, Preen DB, Richmond PC, et al.; WAIVE Study Team. The"], ["", "impact of influenza infection on young children, their family and the"], ["Book Online): https://redbook.solutions.aap.org/selfserve/", ""], ["", "health  care  system.  Influenza  Other  Respir  Viruses  2019;13:18\u201327."], ["sspage.aspx?selfservecontentid=influenza-resources", ""], ["", "PMID:30137663 https://doi.org/10.1111/irv.12604"], ["", "11. Fiore AE, Uyeki TM, Broder K, et al.; CDC. Prevention and control of"], ["Infectious Diseases Society of America Guidance", ""], ["", "influenza with vaccines: recommendations of the Advisory Committee"], ["for Vaccination of Immunocompromised Hosts", "on  Immunization  Practices  (ACIP),  2010.  MMWR  Recomm  Rep"], ["", "2010;59(No. RR-8):1\u201362. PMID:20689501"], ["\u2022  2013 IDSA Clinical Practice Guideline for Vaccination", "12. CDC. How flu vaccine effectiveness and efficacy are measured: questions"], ["of the Immunocompromised Host: https://academic.oup.", "and  answers.  Atlanta,  GA:  US  Department  of  Health  and  Human"], ["", "Services,  CDC;  2016.  https://www.cdc.gov/flu/vaccines-work/"], ["com/cid/article/58/3/e44/336537", ""], ["", "effectivenessqa.htm"], ["", "13. Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of"], ["American College of Obstetricians and", ""], ["", "seasonal influenza in the United States: a tool for strengthening influenza"], ["Gynecologists", "surveillance  and  preparedness.  Influenza  Other  Respir  Viruses"], ["", "2018;12:132\u20137. PMID:29446233 https://doi.org/10.1111/irv.12486"], ["\u2022  Influenza  Vaccination  During  Pregnancy,  ACOG", ""], ["", "14. Rolfes  MA,  Flannery  B,  Chung  JR,  et  al.;  US  Influenza  Vaccine"], ["Committee  Opinion  No.  732:  https://www.acog.org/", "Effectiveness (Flu VE) Network; Influenza Hospitalization Surveillance"], ["", "Network; Assessment Branch, Immunization Services Division, CDC."], ["clinical/clinical-guidance/committee-opinion/", ""], ["", "Effects of influenza vaccination in the United States during the 2017\u2013"], ["articles/2018/04/influenza-vaccination-during-pregnancy", ""], ["", "2018  influenza  season.  Clin  Infect  Dis  2019;69:1845\u201353."], ["", "PMID:30715278 https://doi.org/10.1093/cid/ciz075"], ["References", ""], ["", "15. CDC. 2020\u201321 flu season summary FAQ. Atlanta, GA: US Department"], ["1. Barker WH. Excess pneumonia and influenza associated hospitalization", "of Health and Human Services, CDC; 2021. https://www.cdc.gov/flu/"], ["during influenza epidemics in the United States, 1970\u201378. Am J Public", "season/faq-flu-season-2020-2021.htm"], ["Health  1986;76:761\u20135.  PMID:3717461  https://doi.org/10.2105/", "16. CDC. Fluview. Weekly influenza surveillance report. Atlanta, GA: US"], ["AJPH.76.7.761", "Department of Health and Human Services, CDC; 2021. https://www."], ["2. Barker  WH,  Mullooly  JP.  Impact  of  epidemic  type  A  influenza  in  a", "cdc.gov/flu/weekly/index.htm"], ["defined  adult  population.  Am  J  Epidemiol  1980;112:798\u2013811.", "17. Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control"], ["PMID:7457471 https://doi.org/10.1093/oxfordjournals.aje.a113052", "of seasonal influenza with vaccines: recommendations of the Advisory"], ["3. Coleman  BL,  Fadel  SA,  Fitzpatrick T, Thomas  SM.  Risk  factors  for", "Committee  on  Immunization  Practices,  United  States,  2021\u201322"], ["serious outcomes associated with influenza illness in high- versus low-", "influenza  season.  MMWR  Recomm  Rep  2021;70(No.  RR-5):1\u201328."], ["and  middle-income  countries:  systematic  literature  review  and  meta-", "PMID:34448800 https://doi.org/10.15585/mmwr.rr7005a1"], ["analysis. Influenza Other Respir Viruses 2018;12:22\u20139. PMID:29197154", "18. Ahmed  F.  ACIP  handbook  for  developing  evidence-based"], ["https://doi.org/10.1111/irv.12504", "recommendations, Version 1.2. Atlanta, GA: US Department of Health"], ["", "and Human Services, CDC; 2013."]]}
{"id": "68a95201-67ef-4e83-86c1-4e0de3557cac", "page": 25, "type": "table", "data": [["Recommendations and Reports", ""], ["19. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J,", "32. Ferdinands  JM,  Gaglani  M,  Martin  ET,  et  al.  Waning  vaccine"], ["VanWormer JJ. Waning vaccine protection against influenza A (H3N2)", "effectiveness against influenza-associated hospitalizations among adults,"], ["illness  in  children  and  older  adults  during  a  single  season.  Vaccine", "2015\u20132016 to 2018\u20132019, United States Hospitalized Adult Influenza"], ["2015;33:246\u201351.  PMID:24962752  https://doi.org/10.1016/j.", "Vaccine  Effectiveness  Network.  Clin  Infect  Dis  2021;73:726\u20139."], ["vaccine.2014.06.052", "PMID:33462610 https://doi.org/10.1093/cid/ciab045"], ["20. Radin  JM,  Hawksworth  AW,  Myers  CA,  Ricketts  MN,  Hansen  EA,", "33. Madhi SA, Cutland CL, Kuwanda L, et al.; Maternal Flu Trial (Matflu)"], ["Brice  GT.  Influenza  vaccine  effectiveness:  maintained  protection", "Team. Influenza vaccination of pregnant women and protection of their"], ["throughout  the  duration  of  influenza  seasons  2010\u20132011  through", "infants. N Engl J Med 2014;371:918\u201331. PMID:25184864 https://doi."], ["2013\u20132014. Vaccine 2016;34:3907\u201312. PMID:27265447 https://doi.", "org/10.1056/NEJMoa1401480"], ["org/10.1016/j.vaccine.2016.05.034", "34. Tapia MD, Sow SO, Tamboura B, et al. Maternal immunisation with"], ["21. Ray  GT,  Lewis  N,  Klein  NP,  et  al.  Intraseason  waning  of  influenza", "trivalent  inactivated  influenza  vaccine  for  prevention  of  influenza  in"], ["vaccine effectiveness. Clin Infect Dis 2019;68:1623\u201330. PMID:30204855", "infants  in  Mali:  a  prospective,  active-controlled,  observer-blind,"], ["https://doi.org/10.1093/cid/ciy770", "randomised  phase  4  trial.  Lancet  Infect  Dis  2016;16:1026\u201335."], ["22. Powell LN, B\u00e9gu\u00e9 RE. Influenza vaccine effectiveness among children", "PMID:27261067 https://doi.org/10.1016/S1473-3099(16)30054-8"], ["for the 2017\u20132018 season. J Pediatric Infect Dis Soc 2020;9:468\u201373.", "35. Steinhoff  MC,  Katz  J,  Englund  JA,  et  al.  Year-round  influenza"], ["PMID:31774120 https://doi.org/10.1093/jpids/piz077", "immunisation  during  pregnancy  in  Nepal:  a  phase  4,  randomised,"], ["23. Castilla  J,  Mart\u00ednez-Baz  I,  Mart\u00ednez-Artola V,  et  al.;  Primary  Health", "placebo-controlled  trial.  Lancet  Infect  Dis  2017;17:981\u20139."], ["Care Sentinel Network; Network for Influenza Surveillance in Hospitals", "PMID:28522338 https://doi.org/10.1016/S1473-3099(17)30252-9"], ["of Navarre. Decline in influenza vaccine effectiveness with time after", "36. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza"], ["vaccination,  Navarre,  Spain,  season  2011/12.  Euro  Surveill", "immunization in mothers and infants. N Engl J Med 2008;359:1555\u201364."], ["2013;18:20388.  PMID:23399423  https://doi.org/10.2807/", "PMID:18799552 https://doi.org/10.1056/NEJMoa0708630"], ["ese.18.05.20388-en", "37. CDC. The  flu  season.  Atlanta,  GA:  US  Department  of  Health  and"], ["24. Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine", "Human Services, CDC; 2015. https://www.cdc.gov/flu/about/season/"], ["effectiveness  against  influenza  A(H3)  in  2011/12  among  vaccination", "flu-season.htm"], ["target groups in Europe: results from the I-MOVE multicentre case-", "38. Young B, Sadarangani S, Jiang L, Wilder-Smith A, Chen MI. Duration of"], ["control study. Euro Surveill 2013;18:20390. PMID:23399425 https://", "influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-"], ["doi.org/10.2807/ese.18.05.20390-en", "regression  of  test-negative  design  case-control  studies.  J  Infect  Dis"], ["25. Ferdinands  JM,  Fry  AM,  Reynolds  S,  et  al.  Intraseason  waning  of", "2018;217:731\u201341. PMID:29220496 https://doi.org/10.1093/infdis/jix632"], ["influenza vaccine protection: evidence from the US Influenza Vaccine", "39. Ferdinands JM, Alyanak E, Reed C, Fry AM. Waning of influenza vaccine"], ["Effectiveness  Network,  2011\u201312  through  2014\u201315.  Clin  Infect  Dis", "protection:  exploring  the  trade-offs  of  changes  in  vaccination  timing"], ["2017;64:544\u201350. PMID:28039340", "among older adults. Clin Infect Dis 2020;70:1550\u20139. PMID:31257422"], ["26. Puig-Barber\u00e0  J,  Mira-Iglesias  A, Tortajada-Girb\u00e9s  M,  et  al.;  Valencia", "https://doi.org/10.1093/cid/ciz452"], ["Hospital  Network  for  the  Study  of  Influenza  and  other  Respiratory", "40. Advisory Committee on Immunization Practices; CDC. Immunization"], ["Viruses (VAHNSI, Spain). Waning protection of influenza vaccination", "of health-care personnel: recommendations of the Advisory Committee"], ["during  four  influenza  seasons,  2011/2012  to  2014/2015.  Vaccine", "on  Immunization  Practices  (ACIP).  MMWR  Recomm  Rep"], ["2017;35:5799\u2013807.  PMID:28941618  https://doi.org/10.1016/j.", "2011;60(No. RR-7):1\u201345. PMID:22108587"], ["vaccine.2017.09.035", "41. Pearson  ML,  Bridges  CB,  Harper  SA;  Healthcare  Infection  Control"], ["27. Kissling E, Nunes B, Robertson C, et al.; I-MOVE case\u2013control study", "Practices  Advisory  Committee  (HICPAC);  Advisory  Committee  on"], ["team. I-MOVE multicentre case-control study 2010/11 to 2014/15: is", "Immunization  Practices  (ACIP).  Influenza  vaccination  of  healthcare"], ["there  within-season  waning  of  influenza  type/subtype  vaccine", "personnel:  recommendations  of  the  Healthcare  Infection  Control"], ["effectiveness  with  increasing  time  since  vaccination?  Euro  Surveill", "Practices Advisory Committee (HICPAC) and the Advisory Committee"], ["2016;21.  PMID:27124420  https://doi.org/10.2807/1560-7917.", "on  Immunization  Practices  (ACIP).  MMWR  Recomm  Rep"], ["ES.2016.21.16.30201", "2006;55(No. RR-2):1\u201316. PMID:16498385"], ["28. Pebody R, Andrews N, McMenamin J, et al. Vaccine effectiveness of", "42. Kroger  A,  Bahta  L,  Hunter  P.  General  best  practice  guidelines  for"], ["2011/12 trivalent seasonal influenza vaccine in preventing laboratory-", "immunization: best practices guidance of the Advisory Committee on"], ["confirmed influenza in primary care in the United Kingdom: evidence", "Immunization  Practices  (ACIP).  https://www.cdc.gov/vaccines/hcp/"], ["of  waning  intra-seasonal  protection.  Euro  Surveill  2013;18:20389.", "acip-recs/general-recs/index.html"], ["PMID:23399424 https://doi.org/10.2807/ese.18.05.20389-en", "43. Afluria  Quadrivalent  [Package  Insert].  Parkville,  Victoria,  Australia:"], ["29. Ng Y, Nandar K, Chua LAV, et al. Evaluating the effectiveness of the", "Seqirus; 2022."], ["influenza vaccine during respiratory outbreaks in Singapore\u2019s long term", "44. Fluzone Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2022."], ["care  facilities,  2017.  Vaccine  2019;37:3925\u201331.  PMID:31160102", "45. Neuzil  KM,  Jackson  LA,  Nelson  J,  et  al.  Immunogenicity  and"], ["https://doi.org/10.1016/j.vaccine.2019.03.054", "reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine"], ["30. Young BE, Mak TM, Ang LW, et al. Influenza vaccine failure in the", "in vaccine-naive 5\u20138-year-old children. J Infect Dis 2006;194:1032\u20139."], ["tropics: a retrospective cohort study of waning effectiveness. Epidemiol", "PMID:16991077 https://doi.org/10.1086/507309"], ["Infect  2020;148:e299.  PMID:33261680  https://doi.org/10.1017/", "46. Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness"], ["S0950268820002952", "in healthy 6- to 21-month-old children during the 2003\u20132004 season."], ["31. Mira-Iglesias A, L\u00f3pez-Labrador FX, Garc\u00eda-Rubio J, et al. Influenza", "J Pediatr 2006;149:755\u201362. PMID:17137887 https://doi.org/10.1016/j."], ["vaccine  effectiveness  and  waning  effect  in  hospitalized  older  adults.", "jpeds.2006.06.036"], ["Valencia Region, Spain, 2018/2019 season. Int J Environ Res Public", "47. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK."], ["Health  2021;18:1129.  PMID:33514058  https://doi.org/10.3390/", "Effectiveness of the 2003\u20132004 influenza vaccine among children 6 months"], ["ijerph18031129", "to  8  years  of  age,  with  1  vs  2  doses.  Pediatrics  2005;116:153\u20139."], ["", "PMID:15995046 https://doi.org/10.1542/peds.2005-0049"]]}
{"id": "2587d202-b1ae-4edb-ad7e-07d6e4533c0e", "page": 26, "type": "table", "data": [["Recommendations and Reports", ""], ["48. Eisenberg  KW,  Szilagyi  PG,  Fairbrother  G,  et  al.;  New  Vaccine", "62. Donahue  JG,  Kieke  BA,  King  JP,  et  al.  Association  of  spontaneous"], ["Surveillance Network. Vaccine effectiveness against laboratory-confirmed", "abortion  with  receipt  of  inactivated  influenza  vaccine  containing"], ["influenza in children 6 to 59 months of age during the 2003\u20132004 and", "H1N1pdm09 in 2010\u201311 and 2011\u201312. Vaccine 2017;35:5314\u201322."], ["2004\u20132005  influenza  seasons.  Pediatrics  2008;122:911\u20139.", "PMID:28917295 https://doi.org/10.1016/j.vaccine.2017.06.069"], ["PMID:18977968 https://doi.org/10.1542/peds.2007-3304", "63. Donahue JG, Kieke BA, King JP, et al. Inactivated influenza vaccine and"], ["49. Eick AA, Uyeki TM, Klimov A, et al. Maternal influenza vaccination", "spontaneous  abortion  in  the  Vaccine  Safety  Datalink  in  2012\u201313,"], ["and effect on influenza virus infection in young infants. Arch Pediatr", "2013\u201314, and 2014\u201315. Vaccine 2019;37:6673\u201381. PMID:31540812"], ["Adolesc  Med  2011;165:104\u201311.  PMID:20921345  https://doi.", "https://doi.org/10.1016/j.vaccine.2019.09.035"], ["org/10.1001/archpediatrics.2010.192", "64. Thompson WW,  Shay  DK, Weintraub  E,  et  al.  Mortality  associated"], ["50. ACOG Committee on Obstetric Practice. ACOG Committee opinion", "with influenza and respiratory syncytial virus in the United States. JAMA"], ["no.  732:  influenza  vaccination  during  pregnancy.  Obstet  Gynecol", "2003;289:179\u201386.  PMID:12517228  https://doi.org/10.1001/"], ["2018;131:e109\u201314.  PMID:29578985  https://doi.org/10.1097/", "jama.289.2.179"], ["AOG.0000000000002588", "65. CDC.  Past  seasons  vaccine  effectiveness  estimates.  Atlanta,  GA:  US"], ["51. Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/", "Department of Health and Human Services, CDC. https://www.cdc."], ["H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am", "gov/flu/vaccines-work/past-seasons-estimates.html#2021"], ["J  Obstet  Gynecol  2012;207:177.e1\u20138.  PMID:22939717  https://doi.", "66. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose"], ["org/10.1016/j.ajog.2012.07.007", "versus standard-dose influenza vaccine in older adults. N Engl J Med"], ["52. Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1)", "2014;371:635\u201345.  PMID:25119609  https://doi.org/10.1056/"], ["v2009: a controlled observational prospective cohort study on vaccine", "NEJMoa1315727"], ["safety  in  pregnancy.  Vaccine  2012;30:4445\u201352.  PMID:22564554", "67. Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity"], ["https://doi.org/10.1016/j.vaccine.2012.04.081", "of recombinant influenza hemagglutinin (rHA) and trivalent inactivated"], ["53. Pasternak  B,  Svanstr\u00f6m  H,  M\u00f8lgaard-Nielsen  D,  et  al.  Vaccination", "vaccine (TIV) among persons > or =65 years old. Vaccine 2009;28:379\u201385."], ["against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal", "PMID:19879222 https://doi.org/10.1016/j.vaccine.2009.10.037"], ["death: cohort study in Denmark. BMJ 2012;344:e2794. PMID:22551713", "68. Dunkle LM, Izikson R, Patriarca P, et al.; PSC12 Study Team. Efficacy"], ["https://doi.org/10.1136/bmj.e2794", "of  recombinant  influenza  vaccine  in  adults  50  years  of  age  or  older."], ["54. Sammon  CJ,  Snowball  J,  McGrogan  A,  de Vries  CS.  Evaluating  the", "N  Engl  J  Med  2017;376:2427\u201336.  PMID:28636855  https://doi."], ["hazard  of  foetal  death  following  H1N1  influenza  vaccination;  a", "org/10.1056/NEJMoa1608862"], ["population  based  cohort  study  in  the  UK  GPRD.  PLoS  One", "69. Shay DK, Chillarige Y, Kelman J, et al. Comparative effectiveness of"], ["2012;7:e51734.  PMID:23341865  https://doi.org/10.1371/journal.", "high-dose versus standard-dose influenza vaccines among US Medicare"], ["pone.0051734", "beneficiaries in preventing postinfluenza deaths during 2012\u20132013 and"], ["55. Chambers CD, Johnson D, Xu R, et al.; OTIS Collaborative Research", "2013\u20132014. J Infect Dis 2017;215:510\u20137. PMID:28329311 https://"], ["Group.  Risks  and  safety  of  pandemic  H1N1  influenza  vaccine  in", "doi.org/10.1093/infdis/jiw641"], ["pregnancy: birth defects, spontaneous abortion, preterm delivery, and", "70. Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of cell-"], ["small  for  gestational  age  infants.  Vaccine  2013;31:5026\u201332.", "cultured and egg-based influenza vaccines among elderly persons in the"], ["PMID:24016809 https://doi.org/10.1016/j.vaccine.2013.08.097", "United  States,  2017\u20132018.  J  Infect  Dis  2019;220:1255\u201364."], ["56. Huang  WT, Tang  FW,  Yang  SE,  Chih  YC,  Chuang  JH.  Safety  of", "PMID:30561688 https://doi.org/10.1093/infdis/jiy716"], ["inactivated  monovalent  pandemic  (H1N1)  2009  vaccination  during", "71. Izurieta  HS,  Chillarige  Y,  Kelman  J,  et  al.  Relative  effectiveness  of"], ["pregnancy: a population-based study in Taiwan. Vaccine 2014;32:6463\u20138.", "influenza vaccines among the United States elderly, 2018\u20132019. J Infect"], ["PMID:25285884 https://doi.org/10.1016/j.vaccine.2014.09.054", "Dis  2020;222:278\u201387.  PMID:32100009  https://doi.org/10.1093/"], ["57. Ma F, Zhang L, Jiang R, et al. Prospective cohort study of the safety of", "infdis/jiaa080"], ["an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine", "72. Izurieta  HS,  Lu  M,  Kelman  J,  et  al.  Comparative  effectiveness  of"], ["Immunol 2014;21:1282\u20137. PMID:24990911 https://doi.org/10.1128/", "influenza vaccines among U.S. Medicare beneficiaries ages 65 years and"], ["CVI.00375-14", "older during the 2019\u201320 season. Clin Infect Dis 2021;73:e4251\u20139."], ["58. Chambers CD, Johnson DL, Xu R, et al.; OTIS Collaborative Research", "https://doi.org/10.1093/cid/ciaa1727"], ["Group.  Safety  of  the  2010\u201311,  2011\u201312,  2012\u201313,  and  2013\u201314", "73. Lu Y, Chillarige Y, Izurieta HS, et al. Effect of age on relative effectiveness"], ["seasonal  influenza  vaccines  in  pregnancy:  birth  defects,  spontaneous", "of high-dose versus standard-dose influenza vaccines among US Medicare"], ["abortion, preterm delivery, and small for gestational age infants, a study", "beneficiaries  aged  \u226565  years.  J  Infect  Dis  2019;220:1511\u201320."], ["from  the  cohort  arm  of  VAMPSS.  Vaccine  2016;34:4443\u20139.", "PMID:31290553 https://doi.org/10.1093/infdis/jiz360"], ["PMID:27449682 https://doi.org/10.1016/j.vaccine.2016.06.054", "74. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of"], ["59. McMillan  M,  Porritt  K,  Kralik  D,  Costi  L,  Marshall  H.  Influenza", "high-dose versus standard-dose influenza vaccines in US residents aged"], ["vaccination  during  pregnancy:  a  systematic  review  of  fetal  death,", "65  years  and  older  from  2012  to  2013  using  Medicare  data:  a"], ["spontaneous abortion, and congenital malformation safety outcomes.", "retrospective  cohort  analysis.  Lancet  Infect  Dis  2015;15:293\u2013300."], ["Vaccine 2015;33:2108\u201317. PMID:25758932 https://doi.org/10.1016/j.", "PMID:25672568 https://doi.org/10.1016/S1473-3099(14)71087-4"], ["vaccine.2015.02.068", "75. Richardson  DM,  Medvedeva  EL,  Roberts  CB,  Linkin  DR;  CDC"], ["60. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza", "Epicenter  Program.  Comparative  effectiveness  of  high-dose  versus"], ["immunization and birth outcomes of stillbirth and spontaneous abortion:", "standard-dose influenza vaccination in community-dwelling veterans."], ["a systematic review and meta-analysis. Clin Infect Dis 2015;60:e11\u20139.", "Clin  Infect  Dis  2015;61:171\u20136.  PMID:25829001  https://doi."], ["PMID:25409473 https://doi.org/10.1093/cid/ciu915", "org/10.1093/cid/civ261"], ["61. Irving  SA,  Kieke  BA,  Donahue  JG,  et  al.;  Vaccine  Safety  Datalink.", "76. Young-Xu  Y,  Van  Aalst  R,  Mahmud  SM,  et  al.  Relative  vaccine"], ["Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet", "effectiveness of high-dose versus standard-dose influenza vaccines among"], ["Gynecol 2013;121:159\u201365. PMID:23262941 https://doi.org/10.1097/", "Veterans Health Administration patients. J Infect Dis 2018;217:1718\u201327."], ["AOG.0b013e318279f56f", "PMID:29452380 https://doi.org/10.1093/infdis/jiy088"]]}
{"id": "e989147d-76bf-40e3-8536-e3f92cf15ddc", "page": 27, "type": "table", "data": [["Recommendations and Reports", ""], ["77. Young-Xu Y, Snider JT, van Aalst R, et al. Analysis of relative effectiveness", "91. CDC. Influenza antiviral medications: summary for clinicians. Atlanta,"], ["of  high-dose  versus  standard-dose  influenza  vaccines  using  an", "GA: US Department of Health and Human Services, CDC. https://"], ["instrumental  variable  method.  Vaccine  2019;37:1484\u201390.", "www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm."], ["PMID:30745146 https://doi.org/10.1016/j.vaccine.2019.01.063", ""], ["", "92. Woo EJ. Allergic reactions after egg-free recombinant influenza vaccine:"], ["78. Young-Xu Y, Thornton Snider J, Mahmud SM, et al. High-dose influenza", ""], ["", "reports to the US Vaccine Adverse Event Reporting System. Clin Infect Dis"], ["vaccination and mortality among predominantly male, white, senior veterans,", ""], ["", "2015;60:777\u201380. PMID:25428412 https://doi.org/10.1093/cid/ciu948"], ["United States, 2012/13 to 2014/15. Euro Surveill 2020;25. PMID:32431290", ""], ["", "93. Woo  EJ,  Moro  PL,  Cano  M,  Jankosky  C.  Postmarketing  safety"], ["https://doi.org/10.2807/1560-7917.ES.2020.25.19.1900401", ""], ["", "surveillance of trivalent recombinant influenza vaccine: reports to the"], ["79. Pelton  SI,  Divino  V,  Shah  D,  et  al.  Evaluating  the  relative  vaccine", ""], ["effectiveness  of  adjuvanted  trivalent  influenza  vaccine  compared  to", "Vaccine Adverse Event Reporting System. Vaccine 2017;35:5618\u201321."], ["high-dose trivalent and other egg-based influenza vaccines among older", "PMID:28886946 https://doi.org/10.1016/j.vaccine.2017.08.047"], ["adults in the US during the 2017\u20132018 influenza season. Vaccines (Basel)", "94. Woo EJ, Moro PL. Postmarketing safety surveillance of quadrivalent"], ["2020;8:446. PMID:32784684 https://doi.org/10.3390/vaccines8030446", "recombinant influenza vaccine: Reports to the Vaccine Adverse Event"], ["80. van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of", "Reporting System. Vaccine 2021;39:1812\u20137. PMID:33678452 https://"], ["high dose versus adjuvanted influenza vaccine: a retrospective cohort", ""], ["", "doi.org/10.1016/j.vaccine.2021.02.052"], ["study.  Vaccine  2020;38:372\u20139.  PMID:31606249  https://doi.", ""], ["", "95. Uyeki TM, Zane SB, Bodnar UR, et al.; Alaska/Yukon Territory Respiratory"], ["org/10.1016/j.vaccine.2019.09.105", ""], ["", "Outbreak Investigation Team. Large summertime influenza A outbreak"], ["81. Pelton  SI,  Divino  V,  Postma  MJ,  et  al.  A  retrospective  cohort  study", ""], ["", "among  tourists  in  Alaska  and  the  Yukon Territory.  Clin  Infect  Dis"], ["assessing relative effectiveness of adjuvanted versus high-dose trivalent", ""], ["", "2003;36:1095\u2013102. PMID:12715302 https://doi.org/10.1086/374053"], ["influenza vaccines among older adults in the United States during the", ""], ["2018\u201319 influenza season. Vaccine 2021;39:2396\u2013407. PMID:33810903", "96. Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in"], ["https://doi.org/10.1016/j.vaccine.2021.03.054", "travelers  to  tropical  and  subtropical  countries.  Clin  Infect  Dis"], ["82. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ,", "2005;40:1282\u20137. PMID:15825030 https://doi.org/10.1086/429243"], ["Greenberg DP. Prevention of serious events in adults 65 years of age or", "97. Ratnam I, Black J, Leder K, et al. Incidence and risk factors for acute"], ["older: a comparison between high-dose and standard-dose inactivated", "respiratory illnesses and influenza virus infections in Australian travellers"], ["influenza vaccines. Vaccine 2015;33:4988\u201393. PMID:26212007 https://", ""], ["", "to  Asia.  J  Clin  Virol  2013;57:54\u20138.  PMID:23380660  https://doi."], ["doi.org/10.1016/j.vaccine.2015.07.006", ""], ["", "org/10.1016/j.jcv.2013.01.008"], ["83. Vardeny  O,  Kim  K,  Udell  JA,  et  al.;  INVESTED  Committees  and", ""], ["", "98. Millman AJ, Kornylo Duong K, Lafond K, Green NM, Lippold SA,"], ["Investigators. Effect of high-dose trivalent vs standard-dose quadrivalent", ""], ["", "Jhung MA. Influenza outbreaks among passengers and crew on two"], ["influenza vaccine on mortality or cardiopulmonary hospitalization in", ""], ["", "cruise ships: a recent account of preparedness and response to an ever-"], ["patients with high-risk cardiovascular disease: a randomized clinical trial.", ""], ["JAMA  2021;325:39\u201349.  PMID:33275134  https://doi.org/10.1001/", "present challenge. J Travel Med 2015;22:306\u201311. PMID:26031322"], ["jama.2020.23649", "https://doi.org/10.1111/jtm.12215"], ["84. Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness", "99. Flumist  Quadrivalent  [Package  Insert].  Gaithersburg,  MD:"], ["of high-dose versus standard-dose influenza vaccination on numbers of", "MedImmune; 2021."], ["US nursing home residents admitted to hospital: a cluster-randomised", "100. Rapivab  (peramivir  for  injection)  [Package  Insert].  Durham,  NC:"], ["trial. Lancet Respir Med 2017;5:738\u201346. PMID:28736045 https://doi.", ""], ["", "BioCryst; 2017."], ["org/10.1016/S2213-2600(17)30235-7", ""], ["", "101. Xofluza  (baloxavir  marboxil)  [Package  Insert].  San  Francisco,  CA:"], ["85. McConeghy KW, Davidson HE, Canaday DH, et al. Cluster-randomized", ""], ["", "Genentech;  2018.  https://www.accessdata.fda.gov/drugsatfda_docs/"], ["trial of adjuvanted versus nonadjuvanted trivalent influenza vaccine in", ""], ["", "label/2018/210854s000lbl.pdf"], ["823  US  nursing  homes.  Clin  Infect  Dis  2021;73:e4237\u201343.", ""], ["", "102. Food and Drug Administration. Guidance for industry: bioavailability"], ["PMID:32882710 https://doi.org/10.1093/cid/ciaa1233", ""], ["86. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized,", "and  bioequivalence  studies  for  orally  administered  drug  products:"], ["double-blind controlled phase 3 trial comparing the immunogenicity", "general considerations. Silver Spring, MD: US Department of Health"], ["of high-dose and standard-dose influenza vaccine in adults 65 years of", "and Human Services, Food and Drug Administration; 2003."], ["age and older. J Infect Dis 2009;200:172\u201380. PMID:19508159 https://", "103. Izikson R, Brune D, Bolduc JS, et al. Safety and immunogenicity of a"], ["doi.org/10.1086/599790", ""], ["", "high-dose quadrivalent influenza vaccine administered concomitantly"], ["87. Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and", ""], ["", "with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults"], ["immunogenicity  of  an  MF59\u00ae-adjuvanted  with  a  non-adjuvanted", ""], ["", "aged \u226565 years: a phase 2, randomised, open-label study. Lancet Respir"], ["seasonal influenza vaccine in elderly subjects. Vaccine 2014;32:5027\u201334.", ""], ["", "Med 2022;10:392\u2013402. Epub Feb. 21, 2022. PMID:35114141 https://"], ["PMID:25045825 https://doi.org/10.1016/j.vaccine.2014.07.013", ""], ["", "doi.org/10.1016/S2213-2600(21)00557-9"], ["88. Schmader KE, Liu CK, Harrington T, et al. Safety, reactogenicity, and", ""], ["", "104. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity"], ["health-related quality of life after trivalent adjuvanted vs trivalent high-", ""], ["", "profile  of  the  concomitant  administration  of  ZOSTAVAX  and"], ["dose inactivated influenza vaccines in older adults: a randomized clinical", ""], ["", "inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr"], ["trial. JAMA Netw Open 2021;4:e2031266. PMID:33443580 https://", ""], ["", "So c   2 0 0 7 ; 5 5 : 1 4 9 9 \u2013 5 0 7 .  P M I D : 1 7 9 0 8 0 5 5  h t t p s : / / d o i ."], ["doi.org/10.1001/jamanetworkopen.2020.31266", ""], ["", "org/10.1111/j.1532-5415.2007.01397.x"], ["89. Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised", ""], ["", "105. Levin MJ, Buchwald UK, Gardner J, et al. Immunogenicity and safety"], ["persons. Hum Vaccin Immunother 2018;14:1311\u201322. PMID:29485353", ""], ["", "of zoster vaccine live administered with quadrivalent influenza virus"], ["https://doi.org/10.1080/21645515.2018.1445446", ""], ["", "vaccine.  Vaccine  2018;36:179\u201385.  PMID:28830693  https://doi."], ["90. Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society", ""], ["", "org/10.1016/j.vaccine.2017.08.029"], ["of America. 2013 IDSA clinical practice guideline for vaccination of", ""], ["the  immunocompromised  host.  Clin  Infect  Dis  2014;58:e44\u2013100.", ""], ["PMID:24311479 https://doi.org/10.1093/cid/cit684", ""]]}
{"id": "618f20e3-663d-417c-ade5-373c27980246", "page": 28, "type": "table", "data": [["Recommendations and Reports", ""], ["106. Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled", "115. Li  R,  Stewart  B,  McNeil  MM,  et  al.  Post  licensure  surveillance  of"], ["trial  of  a  13-valent  pneumococcal  conjugate  vaccine  administered", "influenza vaccines in the Vaccine Safety Datalink in the 2013\u20132014"], ["concomitantly with an influenza vaccine in healthy adults. Clin Vaccine", "and 2014\u20132015 seasons. Pharmacoepidemiol Drug Saf 2016;25:928\u201334."], ["Immunol  2012;19:1296\u2013303.  PMID:22739693  https://doi.", "PMID:27037540 https://doi.org/10.1002/pds.3996"], ["org/10.1128/CVI.00176-12", "116. Patterson JL, Carapetian SA, Hageman JR, Kelley KR. Febrile seizures."], ["107. Schwarz TF, Flamaing J, R\u00fcmke HC, et al. A randomized, double-blind", "Pediatr  Ann  2013;42:249\u201354.  PMID:24295158  https://doi."], ["trial to evaluate immunogenicity and safety of 13-valent pneumococcal", "org/10.3928/00904481-20131122-09"], ["conjugate vaccine given concomitantly with trivalent influenza vaccine", "117. Nolan T, Bernstein DI, Block SL, et al.; LAIV Study Group. Safety"], ["in adults aged \u226565 years. Vaccine 2011;29:5195\u2013202. PMID:21619909", "and immunogenicity of concurrent administration of live attenuated"], ["https://doi.org/10.1016/j.vaccine.2011.05.031", "influenza vaccine with measles-mumps-rubella and varicella vaccines"], ["108. McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and", "to  infants  12  to  15  months  of  age.  Pediatrics  2008;121:508\u201316."], ["immunogenicity of concomitant and sequential administration of an", "PMID:18310199 https://doi.org/10.1542/peds.2007-1064"], ["adult formulation tetanus and diphtheria toxoids adsorbed combined", "118. Lum  LC,  Borja-Tabora  CF,  Breiman  RF,  et  al.  Influenza  vaccine"], ["with  acellular  pertussis  (Tdap)  vaccine  and  trivalent  inactivated", "concurrently administered with a combination measles, mumps, and"], ["influenza vaccine in adults. Vaccine 2007;25:3464\u201374. PMID:17270320", "rubella  vaccine  to  young  children.  Vaccine  2010;28:1566\u201374."], ["https://doi.org/10.1016/j.vaccine.2006.12.047", "PMID:20003918 https://doi.org/10.1016/j.vaccine.2009.11.054"], ["109. Nakashima  K,  Aoshima  M,  Ohfuji  S,  et  al.  Immunogenicity  of", "119. Shingrix [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline;"], ["simultaneous  versus  sequential  administration  of  a  23-valent", "2017."], ["pneumococcal  polysaccharide  vaccine  and  a  quadrivalent  influenza", "120. Fluad Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2022."], ["vaccine in older individuals: A randomized, open-label, non-inferiority", "121. Heplisav-B [Package Insert]. Emeryville, CA: Dynavax; 2017."], ["trial. Hum Vaccin Immunother 2018;14:1923\u201330. PMID:29561248", "122. Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and"], ["https://doi.org/10.1080/21645515.2018.1455476", "safety of an adjuvanted herpes zoster subunit vaccine coadministered"], ["110. Song  JY,  Cheong  HJ, Tsai TF,  et  al.  Immunogenicity  and  safety  of", "with seasonal influenza vaccine in adults aged 50 years or older. J Infect"], ["concomitant  MF59-adjuvanted  influenza  vaccine  and  23-valent", "Dis  2017;216:1352\u201361.  PMID:29029224  https://doi.org/10.1093/"], ["pneumococcal polysaccharide vaccine administration in older adults.", "infdis/jix481"], ["Vaccine 2015;33:4647\u201352. PMID:25980426 https://doi.org/10.1016/j.", "123. Fluarix  Quadrivalent  [Package  Insert].  Dresden,  Germany:"], ["vaccine.2015.05.003", "GlaxoSmithKline; 2022."], ["111. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Safety of tetanus", "124. FluLaval Quadrivalent [Package Insert]. Quebec City, QC, Canada:"], ["toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza", "ID Biomedical Corporation of Quebec; 2022."], ["vaccinations  in  pregnancy.  Obstet  Gynecol  2015;126:1069\u201374.", "125. Flucelvax Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2022."], ["PMID:26444109 https://doi.org/10.1097/AOG.0000000000001066", "126. Fluzone  High-Dose  Quadrivalent  [Package  Insert].  Swiftwater,  PA:"], ["112. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric", "Sanofi Pasteur; 2022."], ["trivalent  inactivated  influenza  vaccine  and  13-valent  pneumococcal", "127. Flublok Quadrivalent [Package Insert]. Meriden, CT: Protein Sciences; 2022."], ["conjugate vaccine. JAMA Pediatr 2014;168:211\u20139. PMID:24395025", "128. Food  and  Drug  Administration.  Clinical  review:  Flucelvax"], ["https://doi.org/10.1001/jamapediatrics.2013.4469", "Quadrivalent.  Silver  Spring,  MD:  US  Department  of  Health  and"], ["113. Walter EB, Klein NP, Wodi AP, et al. Fever after influenza, diphtheria-", "Human Services, Food and Drug Administration; 2016."], ["tetanus-acellular pertussis, and pneumococcal vaccinations. Pediatrics", "129. Food  and  Drug  Administration.  Clinical  review:  Flucelvax"], ["2020;145:e20191909.  PMID:32029684  https://doi.org/10.1542/", "Quadrivalent.  Silver  Spring,  MD:  US  Department  of  Health  and"], ["peds.2019-1909", "Human Services, Food and Drug Administration; March 2021."], ["114. Duffy J, Weintraub E, Hambidge SJ, et al.; Vaccine Safety Datalink.", "130. Food  and  Drug  Administration.  Clinical  review:  Flucelvax"], ["Febrile  seizure  risk  after  vaccination  in  children  6  to  23  months.", "Quadrivalent.  Silver  Spring,  MD:  US  Department  of  Health  and"], ["Pediatrics  2016;138:e20160320.  PMID:27273711  https://doi.", "Human Services, Food and Drug Administration; October 2021."], ["org/10.1542/peds.2016-0320", ""]]}
{"id": "80990b52-72ae-4fb4-903a-e1517312eb0a", "page": 29, "type": "table", "data": [["Recommendations and Reports"], ["Disclosure of Relationship and Unlabeled Use"], ["All authors have completed and submitted the International Committee of Medical Journal Editors form for the disclosure of potential conflicts of interest."], ["Helen Keipp Talbot reports receiving financial support from CDC. No other potential conflicts of interest were disclosed. This report includes discussion of"], ["the unlabeled use of influenza vaccines in the instance of influenza vaccination of persons with a history of egg allergy. A history of severe allergic reaction"], ["(e.g., anaphylaxis) to the vaccine or any of its components (which include egg for certain vaccines) is a labeled contraindication to receipt of most IIV4s"], ["and LAIV4. However, ACIP recommends that persons with a history of allergic reaction of any severity to egg should receive any licensed, recommended"], ["influenza vaccine that is appropriate for their age and health status. Persons with a history of severe allergic reaction to egg who receive egg-based vaccines (i.e.,"], ["vaccines other than cell culture\u2013based inactivated influenza vaccine [ccIIV4] or recombinant influenza vaccine [RIV4]) should be vaccinated in an inpatient"], ["or outpatient medical setting (including, but not necessarily limited to, hospitals, clinics, health departments, and physician offices); vaccine administration"], ["in such instances should be supervised by a health care provider who is able to recognize and manage severe allergic reactions. No postvaccination waiting"], ["period is recommended specifically for egg-allergic persons. However, ACIP recommends that vaccine providers consider observing patients seated or supine"], ["for 15 minutes after administration of any vaccine (regardless of allergy history) to decrease the risk for injury should syncope occur."]]}
{"id": "9474ddf8-082b-4c60-9f09-aef23e74e193", "page": 30, "type": "table", "data": [["Recommendations and Reports"], ["Advisory Committee on Immunization Practices (ACIP), July 1, 2021\u2013June 30, 2022"], ["Chair: Grace M. Lee, MD, Stanford University School of Medicine, Stanford, California."], ["Executive Secretary: Melinda Wharton, MD, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia."], ["Members: Kevin A. Ault, MD, University of Kansas Medical Center, Kansas City, Kansas; Lynn Bahta, MPH, Minnesota Department of Health, St. Paul,"], ["Minnesota; Beth P. Bell, MD, University of Washington, Seattle, Washington; Oliver Brooks, MD, Watts HealthCare Corporation, Los Angeles, California;"], ["Wilbur H. Chen, MD, University of Maryland School of Medicine, Baltimore, Maryland; Sybil Cineas, MD, Warren Alpert Medical School of Brown"], ["University,  Providence,  Rhode  Island;  Matthew  F.  Daley,  MD,  Kaiser  Permanente  Colorado,  Aurora,  Colorado;  Camille  Nelson  Kotton,  MD,  Harvard"], ["Medical School, Boston, Massachusetts; Jamie Loehr, MD, Cayuga Family Medicine, Ithaca, New York; Sarah S. Long, MD, Drexel University College of"], ["Medicine, Philadelphia, Pennsylvania; Veronica V. McNally, JD, Franny Strong Foundation, West Bloomfield, Michigan; Katherine A. Poehling, MD, Wake"], ["Forest School of Medicine, Winston-Salem, North Carolina; Pablo J. S\u00e1nchez, MD, The Research Institute at Nationwide Children\u2019s Hospital, Columbus,"], ["Ohio; Helen Keipp Talbot, MD, Vanderbilt University, Nashville, Tennessee."], ["Ex Officio Members: Centers for Medicare and Medicaid Services, Mary Beth Hance, Baltimore, Maryland; Food and Drug Administration, Doran Fink,"], ["MD, PhD, Silver Spring, Maryland; Health Resources and Services Administration, Mary Rubin, MD, Rockville, Maryland; Indian Health Service, Matthew"], ["Clark, MD, Durango, Colorado; Office of Infectious Disease and HIV/AIDS Policy, David Kim, MD, Washington, DC; National Institutes of Health, John"], ["Beigel, MD, Bethesda, Maryland."], ["Liaison  Representatives:  American  Academy  of  Family  Physicians,  Pamela  G.  Rockwell,  DO,  Ann  Arbor,  Michigan;  American  Academy  of  Pediatrics,"], ["Committee on Infectious Diseases, Yvonne Maldonado, MD, Stanford, California; American Academy of Pediatrics, Red Book Editor, David Kimberlin, MD,"], ["Birmingham, Alabama; American Academy of Physician Associates, Marie-Mich\u00e8le L\u00e9ger, MPH, Alexandria, Virginia; American College Health Association,"], ["Thevy Chai, MD, Chapel Hill, North Carolina; American College Health Association, (alternate) Sharon McMullen, MPH, Ithaca, New York; American"], ["College of Nurse Midwives, Carol E. Hayes, MN, MPH, Atlanta, Georgia; American College of Nurse Midwives, (alternate) Pamela M. Meharry, PhD,"], ["Chicago, Illinois; American College of Obstetricians and Gynecologists, Linda O\u2019Neal Eckert, MD, Seattle, Washington; American College of Physicians,"], ["Jason M. Goldman, MD, Boca Raton, Florida; American Geriatrics Society, Kenneth Schmader, MD, Durham, North Carolina; America\u2019s Health Insurance"], ["Plans, Robert A. Gluckman, MD, Beaverton, Oregon; American Immunization Registry Association, Rebecca Coyle, MSEd, Washington, DC; American"], ["Medical Association, Sandra Adamson Fryhofer, MD, Atlanta, Georgia; American Nurses Association, Charles (Chad) Rittle, DNP, Pittsburgh, Pennsylvania;"], ["American Osteopathic Association, Stanley E. Grogg, DO, Tulsa, Oklahoma; American Pharmacists Association, Michael D. Hogue, PharmD, Loma Linda,"], ["California; Association of Immunization Managers, Molly Howell, MPH, Bismarck, North Dakota; Association for Prevention Teaching and Research, Richard"], ["Zimmerman, MD, Pittsburgh, Pennsylvania; Association of State and Territorial Health Officials, Nirav Shah, MD, JD, Augusta, Maine; Biotechnology Industry"], ["Organization, Phyllis A. Arthur, MBA, Washington, DC; Council of State and Territorial Epidemiologists, Christine Hahn, MD, Boise, Idaho; Council of State"], ["and Territorial Epidemiologists, (alternate) Susan Lett, MD, Boston, Massachusetts; Canadian National Advisory Committee on Immunization, Shelley Deeks,"], ["MD, Halifax, Nova Scotia, Canada; Infectious Diseases Society of America, Carol J. Baker, MD, Houston, Texas; International Society for Travel Medicine,"], ["Elizabeth D. Barnett, MD, Boston, Massachusetts; National Association of County and City Health Officials, Matthew Zahn, MD, Santa Ana, California;"], ["National Association of County and City Health Officials, (alternate) Jeffrey Duchin, MD, Seattle, Washington; National Association of Pediatric Nurse"], ["Practitioners, Patricia A. Stinchfield, MS, St. Paul, Minnesota; National Foundation for Infectious Diseases, William Schaffner, MD, Nashville, Tennessee;"], ["National Foundation for Infectious Diseases, (alternate) Marla Dalton, Bethesda, Maryland; National Medical Association, Patricia Whitley-Williams, MD,"], ["New Brunswick, New Jersey; Pediatric Infectious Diseases Society, Sean O\u2019Leary, MD, Aurora, Colorado; Pediatric Infectious Diseases Society, (alternate)"], ["Mark H. Sawyer, MD, San Diego, California; Pharmaceutical Research and Manufacturers of America, Corey Robertson, MD, Swiftwater, Pennsylvania;"], ["Society for Adolescent Health and Medicine, Amy B. Middleman, MD, Oklahoma City, Oklahoma; Society for Healthcare Epidemiology of America, Marci"], ["Drees, MD, Philadelphia, Pennsylvania."], ["ACIP Influenza Vaccine Work Group"], ["Chair: H. Keipp Talbot, MD, Nashville, Tennessee."], ["Members: Robert Atmar, MD, Houston, Texas; Kevin Ault, MD, Kansas City, Kansas; Edward Belongia, MD, Marshfield, Wisconsin; Henry Bernstein, DO,"], ["Hempstead, New York; Kristina Angel Bryant, MD, Louisville, Kentucky; Sarah Coles, MD, Phoenix, Arizona; Michael Cooper, PhD, Bethesda, Maryland;"], ["Jeffrey Duchin, MD, Seattle, Washington; Sandra Adamson Fryhofer, MD, Atlanta, Georgia; Denise Jamieson, MD, Atlanta, Georgia; Krissy Moehling Geffel,"], ["PhD, Pittsburgh, Pennsylvania; Wendy Keitel, MD, Houston, Texas; Camille Kotton, MD, Boston, Massachusetts; Marie-Mich\u00e8le L\u00e9ger, MPH, Alexandria,"], ["Virginia; Susan Lett, MD, Boston, Massachusetts; Jamie Loehr, MD, Ithaca, New York; Valerie Marshall, Washington, DC; Mark Mulligan, MD, New York,"], ["New York; Kathleen M. Neuzil, MD, Baltimore, Maryland; Cynthia Nolletti, MD, Silver Spring, Maryland; Jesse Papenburg, Montreal, Quebec, Canada;"], ["William Schaffner, MD, Nashville, Tennessee; Robert Schechter, MD, Richmond, California; Kenneth Schmader, MD, Durham, North Carolina; Tamara"], ["Sheffield, MD, Salt Lake City, Utah; Angela Sinilaite, MPH, Ottawa, Ontario, Canada; Patricia Stinchfield, MS, St. Paul, Minnesota; Peter Szilagyi, MD,"], ["Los Angeles, California; Susan Wollersheim, MD, Silver Spring, Maryland; Matthew Zahn, MD, Santa Ana, California."]]}
{"id": "06080720-f10a-4829-ad04-775be32ba409", "page": 32, "type": "table", "data": [["The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free"], ["of charge in electronic format. To receive an electronic copy each week, visit MMWR at https://www.cdc.gov/mmwr/index.html."], ["Readers  who  have  difficulty  accessing  this  PDF  file  may  access  the  HTML  file  at  https://www.cdc.gov/mmwr/volumes/71/rr/rr7101a1.htm?s_"], ["cid=rr7101a1_w. Address all inquiries about the MMWR Series to Editor-in-Chief, MMWR Series, Mailstop V25-5, CDC, 1600 Clifton Rd., N.E.,"], ["Atlanta, GA 30329-4027 or to mmwrq@cdc.gov."], ["All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated."], ["MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services."], ["Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services."], ["References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations"], ["or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses"], ["listed in MMWR were current as of the date of publication."]]}
